Annual Report 2015 draft as at 23 12 15 (Autosaved)...antidepressant effects. We are completing the first study of minocycline, an antibiotic with anti-inflammatory properties in depression

December 2015 - 2 -

Contents Forewords ……………………………………………………………………...…………………………………………………………………………………………...……….……… _ 3

Introduction by Professor Michael Berk …………………………………………………………………………………...………....….… _ 4

The Epi-Centre for healthy ageing – Professor Julie Pasco ………………………………………..….…… _ 5

Bipolar disorder research – Professor Michael Berk …………………………………………………………..….……… _ 6

Drug safety – Associate Professor Seetal Dodd………………………………………………………………...……………… _ 7

Clinical trials division – Dr Olivia Dean…………………………………………………………………………………………….…….……… _ 8

Psychiatric disorders and co-morbidity – Dr Lana Williams………...………………………...……………… _ 9

Prevention of common mental disorders – Associate Professor Felice Jacka _ 10

Social equity, chronic disease and healthcare utilisation – Dr Sharon Brennan-Olsen ………………………………………………………………………………………………………………………………...……

_

11

Precision Medicine: Genetically guided antidepressants – Associate Professor Ajeet Singh ……………………………………………………………………………………….……...……….……………

_

12

Determining the risk factors for musculoskeletal disorders and conditions in the Australian population – Dr Kara Holloway……………………………………….…………………………...………………

_

12

Inflammatory and neurotrophic biomarkers in bipolar disorder and schizophrenia – Dr Brisa Fernandes …………………………………………………………………………………………………………..……

_ 13

Links between anxiety and smoking – Dr Steven Moylan ……………………………….…...……………… _ 14

Our PhD candidates ……………….……………………………………………………………………………………………………………………...………….…… _ 15-21

Ongoing funding for 2015 ………………………………………………………………………………………………………………………...……………… _ 21-22

Successful grants 2015 ………………………………………………………………………………………………………………………………...……………..… _ 22-23

Awards 2015 …………………………………………….……………………………………………………………………………………………………………...………………. _ 23

International and national collaborations …………………………………………………………………………...…………..…… _ 24

Publications 2015 …………………………………………………………………………………………………………………………………...………………………..…. _ 25-36

Books and chapters 2015…………………………………………………………………………………………...……………………………...………….…… _ 36

Conference presentations 2015……………………………………………….………………………………………………………...……………… _ 37-45

Contact details ………………………………………………………………………………………………………………………………..............................….…………… _ 46

The IMPACT SRC team

December 2015 - 3 -

Forewords

2015 has been a great year for the IMPACT SRC, most notably for Director Michael Berk who received numerous prestigious awards including being named as one of Thomas Reuters most highly cited researchers as well as becoming a Fellow of the Australian Academy of Health and Medical Sciences. His success is largely in part to the excellent staff and students within the Centre and I wish them well for another busy and productive year in 2016.

Professor Lee Astheimer

Deputy Vice Chancellor, Research Deakin University

IMPACT SRC has had a very successful year even by its own high standards. Of particular note the excellent staff members have been acknowledged by a number of prestigious awards. I would like to make special mention of Professor Michael Berk for his leadership and mentoring of the research programme and for this to be recognised with international awards. Well done Michael and your team, thank you for your significant contributions in 2015

Professor David Ashbridge

Chief Executive Officer Barwon Health

IMPACT SRC is a medical research group with an international reputation, in a regional setting. Prof Michael Berk leads the group that, over this last year, has accomplished a great deal. At the review day this year, the Advisory Board was very impressed with what has been and achieved and sees important opportunities going forward. Professor Michael Berk is to be congratulated on his award of the 2015 Brain & Behavior Research Foundation (USA) Colvin Prize for Bipolar Mood Disorder Research, a prestigious international award in his area of research. The Advisory Board is in the process of developing a multi-level program of philanthropic support centred on the excellent work of the IMPACT SRC and drawing attention to its work of international standing. In particular we are developing a program for corporate organisations in mental health.

Trevor M Clark OAM

Director Autism Co-operative Research Centre Chair, IMPACT SRC Advisory Board

December 2015 - 4 -

Introduction by Professor Michael Berk

The IMPACT SRC remains committed to the generation of results that make a direct contribution to the health of the population, and in 2015 we had a number of notable successes. In particular we completed the first study suggesting that simply improving diet might have antidepressant effects. We are completing the first study of minocycline, an antibiotic with anti-inflammatory properties in depression and the first study of a combination of neutraceutical agents that boost mitochondrial energy generation to potentially treat bipolar depression,

A number of members of the team had particular successes:

1. Sarah Dash, PhD candidate was awarded a Top-Up Scholarship, by the Collaborative Research Centre for Mental Health (CRC), 2015.

2. Dr Brisa Fernandes, post-doctoral research fellow, won Best Early-Career Researcher Poster at the 2015 Australasian Society for Bipolar and Depressive Disorders (ASBDD) conference.

3. Melanie Ashton, PhD candidate, was awarded the 2015 ASBDD/Lundbeck Neuroscience Scholarship.

4. Dr Olivia Dean, post-doctoral research fellow, was awarded the 2015 ASBDD/Servier Depression Research Grant.

5. Sue Lauder, PhD candidate, won the Best Early-Career Researcher Oral Presentation at the 2015 ASBDD conference.

6. Dr Sharon Brennan-Olsen, post-doctoral research fellow, was awarded the 2015 Professor Philip Sambrook Award at the Australian and New Zealand Bone and Mineral Society conference (ANZBMS).

7. Dr Lana Williams, post-doctoral research fellow, was awarded a NHMRC project grant for her work investigating bone health in bipolar disorder.

8. Emma Gliddon, PhD candidate, was awarded the inaugural Past District Governor Geoff Betts Early Mental Health Researcher Award from the Rotary Club of Geelong, as well as a Grant-in-Aid for the 2015 Society for Mental Health Research conference.

9. Dr Shae Quirk, post-doctoral research fellow, was awarded the Faculty of Health HDR Publication Award for her thesis submitted in 2015.

10. Prof Michael Berk was listed as an ICI highly cited researcher and won the Brain and Behaviour Foundation Colvin Award.

11. Dr Sharon Brennan-Olsen, post-doctoral research fellow, received a NHMRC Career Development Fellowship.

12. A/Prof Felice Jacka, post-doctoral research fellow, received a NHMRC Career Development Fellowship.

13. Aswin Ratheesh, PhD candidate, was awarded an early career researcher oral communication award from the Australasian Society of Bipolar and Depressive Disorders conference.

We would like to thank Deakin University and Barwon Health for their continuing support.

Professor Michael Berk

December 2015 - 5 -

The Epi-Centre for Healthy Ageing - Professor Julie Pasco

Professor Julie Pasco is Deputy Director of the IMPACT SRC and Director of the Epi-Centre for Healthy Ageing. Her population-based research focuses on understanding the progression of chronic metabolic and musculoskeletal disorders including obesity, diabetes, osteoporosis and sarcopenia, and the nexus between physical and mental health. An important component of this program of epidemiological research is to facilitate knowledge transfer from research into clinical practice and into the community. At the heart of the Epi-Centre for Healthy Ageing lies the Geelong Osteoporosis Study (GOS) which is complemented by the GOS Fracture Grid, and the studies known as Vitamin D in Pregnancy (VIP) and Ageing, Chronic Disease and Injury (ACDI). The GOS is a prospective cohort study, which was designed to describe the health burden of osteoporosis and identify risk factors for fragility fracture, and has evolved over time to study a broad range of chronic disorders. The study is set in the

Barwon Statistical Division. For more than two decades the GOS has prospectively documented comprehensive clinical and environmental data for large contemporary cohorts of young, middle-aged and elderly men and women, producing a unique resource for investigating aspects of both physical and mental health. The GOS Fracture Grid is an ongoing, comprehensive repository that documents incident fractures as they occur in the Barwon Statistical Division. For twenty years this unique dataset has been recording fracture case details according to fracture site, age, sex and date. Data from the GOS Fracture Grid provide a unique evidence base for describing the epidemiology of fractures and for monitoring changes in patterns of fracture for an entire population. The VIP study started in 2002 when pregnant women were recruited from Geelong Hospital’s antenatal clinic and provided blood samples for vitamin D assessment. Their babies were measured at birth and at age one. The mother-child pairs are now being recalled to see if maternal vitamin D status during pregnancy impacts on muscle and bone growth, fat distribution and behaviour in the children as they reach upper primary school age. The ACDI commenced this year, with an overall objective of describing the pattern of chronic disease and injury throughout western Victoria. Data are currently being abstracted from existing health and administrative databases and collated for the twenty-one Local Government Areas in the region in terms of age, sex, socioeconomic status and remoteness. The data will be used to establish and target the appropriate allocation of resources, care transition needs and to deal with burden of disease and injury. Nested within the Epi-Centre for Healthy Ageing are the units of Musculoskeletal Epidemiology (led by Dr Kara Holloway), Social Epidemiology (led by Dr Sharon Brennan-Olsen) and Psychiatric Epidemiology (led by Dr Lana Williams).

December 2015 - 6 -

Bipolar disorder research

Mood disorders are a primary focus of the IMPACT Strategic Research Centre. We aim to answer the question of which potential mood stabilising agents have the best neuroprotective properties after a first-episode of mania. In the study, individuals who have had a first-episode of mania were randomised to receive either lithium or quetiapine and were followed up for a year using brain imaging and neuropsychology to determine which agent best protects the brain. The data suggests that lithium is superior on measures of clinical symptoms, neurocognition and brain imaging, reinforcing its primary role in the disorder. A further focus is on carer-burden in bipolar disorder and depression. A treatment intervention for carers of people with bipolar disorder has been developed, and a parallel resource for carers of people with depression is being completed. Having shown that N-acetylcysteine (NAC) effectively treats negative symptoms of schizophrenia, the symptoms of depression in bipolar disorder and reduces depression in unipolar disorder, we have just completed a study showing that it assists with smoking cessation. We are partnering on replication studies in bipolar disorder and schizophrenia. We have just completed a large NHMRC and CRC funded project to definitively study the efficacy of NAC in bipolar depression, as well as a cocktail of mitochondrially active agents. The latter study is a proof of concept trial of the notion that there is a primary abnormality in mitochondrial energy generation in bipolar disorder – these data will be available in 2016. Together with Dr Sue Tye from the Mayo Clinic, we are developing a novel animal model of bipolar disorder using deep brain stimulation, to examine changes in energy generation in models of both depression and mania. We are grateful for the partnership with Professor Abbas Kouzani from Science, Engineering and Built Environment who leads the development of novel DBS and optogenetic devises for preclinical study, a critical element in this program of research. Professor Ken Walder from the MRR SRC has developed a drug discovery program for diabetes by looking at the gene expression signature of existing agents, and finding new potential treatments that target this gene expression signature. We have developed an NHMRC supported analogous drug discovery program for bipolar disorder in partnership with Professor Walder, and are extending this method to drug discovery in schizophrenia. Lastly, we had surprising success in a pilot clinical trial of Garcinia Mangostana Linn. (mangosteen) in the treatment of schizophrenia, and are replicating this finding schizophrenia in a more definitive Stanley funded grant with John McGrath from Queensland and extending these findings to explore its efficacy in bipolar disorder.

December 2015 - 7 -

Drug safety The large range of medications available for the treatment of mental illness have helped improve the lives of thousands, perhaps even millions of people. These agents have helped people manage their illnesses, prevented or reduced the recurrence of illness and controlled symptoms of illness. Although people with mental health difficulties have benefited greatly from modern drug treatments, these treatments are also known to have risks. Researchers at IMPACT SRC work to understand and reduce the risks and to improve the risk-to-benefit ratios for drug treatment of mental illness. Central to our work in drug safety, we have investigated treatment emergent adverse events in clinical trial data and in other databases. Using adverse event data from clinical trials of duloxetine for major depression we have investigated the complexity of the placebo and nocebo effect, which are important confounders when investigating adverse events. This work was published the Journal of Clinical Psychiatry earlier this

year. Further work is currently underway using clinical trial data from studies of olanzapine for bipolar disorder. Meta-analyses of lurasidone clinical trials are also planned. We are also conducting studies evaluating the neuroprotective properties of conventional and novel treatments. These studies may provide a new treatment objective for people with mental illness, preventing the worsening course of the illness rather than simply reacting to the symptoms of the illness. This new approach to treatment in mental health may ultimately lead to both better mental health and better drug safety outcomes. Chronic, treatment resistant stages of illness are typically associated with higher doses of treatment and drug combinations. If this can be averted through our neuroprotective strategies then drug safety will be improved. In March 2015 Associate Professor Dodd argued for the pro case in a debate titled “Staging should be applied to major psychosis and mood disorders” presented at the 23rd European Congress of Psychiatry, Vienna, Austria. We have also published several papers on oxidative, nitrosative and inflammatory stress, which is core to the topic of neuroprotection, neuroprogression and illness staging. We have been involved in the publication of guidelines, which assist clinicians to make well-informed and balanced treatment decisions. These include publications regarding the safe use of drugs for the evidence-based treatment of various mental illnesses as well as publications about safe treatments in special populations, such as pregnant and breast-feeding women. A major international collaboration to produce antidepressant safety guidelines is currently in progress. Highlighting our role in this drug safety, Associate Professor Seetal Dodd currently holds the position of Editor-in-Chief of the scientific journal Current Drug Safety, which he has held since 2009.

Associate Professor Seetal

Dodd

December 2015 - 8 -

Clinical trials division There is a great need for new therapies for people with mental health disorders. Our Clinical Trials Division is currently focusing on evidence based, adjunctive pharmacotherapies to provide greater recovery for individuals with a variety of psychiatric disorders. The central program of the Division explores the repurposing of existing agents, based on their known biological profiles, to attempt to reduce the symptoms experienced by those with psychiatric disorders. In an iterative approach, the Division incorporates biological sampling (blood samples) and preclinical investigations in collaboration with Laura Gray and Kay Hasebe, PhD candidate, to both identify relevant mechanisms of action for therapeutic targets and better understand the underlying pathophysiology of the illnesses. Our current trials focus on adjunctive therapies to modulate oxidative biology, inflammation, neurogenesis and mitochondrial dysfunction; all factors that are believed to be important in the pathology of many psychiatric illnesses. The current studies are focusing on people with depression, both major depression and those with bipolar disorder, currently experiencing symptoms of depression. Additionally, we have a collaborative study involving the Deakin University/Barwon Health partnership, investigating NAC as a treatment for post-operative cognitive decline (involving PhD candidate David Skvarc in collaboration with lead investigator, Dr Andrew Marriott). These multi-centre trials involve centres located in Australia as well as an international site in Thailand in collaboration with Prof Michael Maes and Associate Professor Buranee Kanchanatawan. The current trials include a new study that extends our previous work with N-acetylcysteine (NAC). This clinical trial involves three treatment arms, a placebo arm, a NAC-alone arm and a combination arm incorporating NAC with other nutraceuticals, believed to alter mitochondrial function. There is mounting evidence to suggest that the symptoms of bipolar disorder are partially driven by changes in our energy powerhouses, the mitochondria. By adding-on nutraceuticals that target mitochondrial function, we are hoping that the symptoms of bipolar disorder may be improved. In another world-first study, we are investigating an antibiotic, minocycline, as a potential adjunctive antidepressant treatment. In addition to being antimicrobial, minocycline has anti-inflammatory properties that may be beneficial for the symptoms of depression. We are also currently investigating the potential of two other anti-inflammatory agents to treat youth depression; rosuvastatin and aspirin. Similar to the minocycline trial, these agents have properties that may be useful in treating youth depression. The benefit of utilising existing agents is that they have known safety profiles with expected side effects and available following completion of the trials, making the IMPACT SRC trials particularly attractive to participants. We have recently completed two trials investigating adjunctive NAC treatment, showing that NAC may be useful for depression. We are currently analysing the results from our recently completed trial for children with autism. We hope to have results available for public dissemination soon. The Clinical Trials Division currently has a register open to anyone who has a psychiatric disorder and would be interested in taking part in our studies. If you would like more information regarding the register, please contact Dr Olivia Dean – (03) 4215 3300.

Dr Olivia Dean

December 2015 - 9 -

Psychiatric disorders and co-morbidity Mood, anxiety and personality disorders impose huge costs, both on the individual and the community, yet we have an incomplete understanding of their impact on lifestyle, social and in particular medical factors. Over the past years, Dr Williams has been developing a program of research investigating medical, lifestyle and social outcomes associated with mood, anxiety and personality disorders. This research has been conducted in conjunction with the Geelong Osteoporosis Study (GOS), a large epidemiological study involving a population-based sample of ~ 3000 randomly-selected men and women. This research has revealed associations between mood and anxiety disorder and a range of medical conditions including osteoporosis, irritable bowel syndrome, atopic disorders, pain and cardiovascular diseases. Associations between mood and anxiety disorders and lifestyle factors such as smoking and physical activity and social factors such as area based socioeconomic status and quality of life have also been explored. A wide range of social, psychological and biological factors such as the presence of inflammation and/or oxidative stress are being investigated, which may explain these associations. Complementing this work is a case-control study of bipolar disorder, designed to identify associated lifestyle and physical co morbidities. Cornerstone to this program is our work investigating the interplay between psychiatric disorders, the medications used to treat these disorders and bone health, which has attracted extensive project funding and personal awards. This project engages experts from the fields of psychiatry, bone biology, epidemiology and translation worldwide to provide a comprehensive understanding of this clinically important but neglected issue. To date, we have found depression to be associated with reduced bone mineral density, affect bone quality and increase the risk of fracture by over 60%. We were also one of the first to show that the SSRI group of antidepressants may increase the risk for osteoporosis and that these agents, in vitro, have marked intra class differences in their effects on bone. The effects of psychoactive drugs on physical health is under further review in a study known as PROFRAC and these relationships are being investigated at the cellular level with collaborators in the laboratories at Barwon Biomedical Research, Deakin University and in Lyon, France. Overall this large program of work generates important information that can be used to provide an insight into the interaction between physical and mental health. It is an invaluable resource for collaborative studies and student projects. Existing collaborations include Norwegian University of Science and Technology, University of Eastern Finland, Institute of Functional Genomics of Lyon, Sapienza Universitsà of Rome, University of Manitoba, which allows for further investigations and replication in even larger population based studies.

Dr Lana Williams: NHMRC

Career Development Fellow

and Head, Psychiatric

Epidemiology.

December 2015 - 10 -

Prevention of common mental disorders

Depression and anxiety are highly prevalent conditions, and the burden they impose on individuals and the community is enormous. In our research unit we have developed a highly innovative program of research that examines how our lifestyles (diet, physical activity and smoking) interact with our risk for mental health problems. This is being done with the ultimate goal of developing an evidence-based public health message for the primary prevention of these common mental disorders. Associate Professor Felice Jacka leads the Division of Nutritional Psychiatry Research within the IMPACT SRC and is also the president of the ‘International Society for Nutritional Psychiatry Research’ (ISNPR). In 2015, the ISNPR strengthened its profile internationally via the publication “Nutritional medicine as mainstream in psychiatry” in Lancet Psychiatry, as well as by publication of the official ISNPR consensus statement in World Psychiatry, the third ranking journal in psychiatry research. Among others, Associate Professor Jacka also published key

papers including dietary recommendations for the prevention of depression, a systematic review of randomised controlled trials of dietary interventions and depression outcomes, a comprehensive assessment showing that healthy diets do not have to be more expensive than unhealthy diets, and the first study to document associations between dietary patterns and hippocampal volume in humans. Along with the ISNPR statements, this latter study received worldwide media coverage. In 2015, the Nutritional Psychiatry Division also built collaboration with the APC Microbiome Institute in Ireland at University College Cork. This institute is recognised as the world leader in the topic of microbiota-gut-brain-axis research and this collaboration has resulted in an application to the NHMRC for the first RCT of probiotics in major depression, led by Associate Professor Jacka. Collaboration with the Murdoch Children’s Research Institute has also seen the development of a highly innovative intervention focused on diet in pregnancy. In this study, Associate Professor Jacka will work with leading epigeneticists, paediatric immunologists and the expert team at the APC to examine the potential impact of dietary improvement in pregnancy on microbiota, epigenetics, inflammation and other relevant biomarkers believed to be linked to the risk for mental and neurodevelopmental disorders in children. Finally, in April 2015 recruitment was finalised for a world’s first trial that aims to answer the important question “If I improve my diet, will my mental health improve?” The final assessment will take place in October and the results will be generated and published soon after.

Associate Professor Felice

Jacka


Social equity, chronic disease and healthcare utilisation

A disproportionate disease burden occurs in disadvantaged and vulnerable populations; indeed, the social gradient of chronic disease and healthcare utilisation has never been as prominent, even in high income countries such as Australia. The program of research undertaken within the Health Inequalities Division of Epidemiology (HIDE) investigates mechanisms that facilitate inequalities in health to bring them ‘out of hiding’. We address the complex, multifactorial pathways between social context, chronic diseases and healthcare utilisation, and more recently have focused on investigating biological mechanisms that might underpin health inequalities. Dr Brennan-Olsen leads the multifaceted program of research encompassed within HIDE. She is also Associate Editor for BMC Musculoskeletal Disorders, and Conjoint Research Fellow with the Institute of Healthy Ageing, Australian Catholic University. In 2015 Dr Brennan-Olsen initiated novel investigations

aimed at explaining the well-documented social gradient of disease; this work focuses on associations between cumulative disadvantage across the life-course and biological mechanisms for disease onset including heightened inflammatory states and DNA methylation, amongst others. This new field of research is supported by an exciting new collaboration established during 2015 between Deakin University, and the University of Western Australia, University of Manitoba (Canada), McGill University (Canada), University of Cantabria (Spain), King’s College (UK), University of Glasgow (UK), and Loyola University (USA). This new alliance will enable a cross-disciplinary approach that extends from basic science through to population health, in a manner that is globally unique. This work resulted in Osteoporosis Australia and the Australian and New Zealand Bone and Mineral Society awarding Dr Brennan-Olsen the prestigious 2015 Professor Philip Sambrook Award. During 2015, a focus was maintained on translating a number of recommended preventive health guidelines into easily accessible messages for the general population, which involved novel collaborations between HIDE and disadvantaged community groups. This work resulted in the development of visual tools to communicate preventive health behaviours, whilst avoiding dependence on literacy or language abilities of the intended audience. One example of this work was an oversized jigsaw that visually ‘pieced together’ preventive lifestyle behaviours related to osteoporosis prevention, and was employed on World Osteoporosis Day. Another example was a ‘Fracture Stack’ that involved regional Primary School children; this work resembled a ‘stack’ of plaster casts that was indicative of the 750 fractures that occur in the Geelong region each month. The Fracture Stack was implemented in public space for during Healthy Bones Action Week. For her work engaging disadvantaged populations in knowledge translation, Dr Brennan-Olsen was awarded the Vice Chancellor’s Early Career Research Award for Excellence in Ideas.

Dr Sharon Brennan-Olsen


Precision Medicine: Genetically guided antidepressants

Genetically guided prescribing (precision medicine) may help sooner match patients to effective tolerable medication. Precision medicine has been identified as a priority area of medical research globally given its potential for improved patient outcomes and reduced costs of care. Exponential cost reductions in genotyping via automation have seen genotyping prices drop from tens of thousands of dollars to (for some gene panels) under AUD$100 in just the last few years. Should clinical utility be demonstrated for superiority of genetically guided prescribing over traditional trial and error prescribing, it’s likely the technology will see rapid clinical uptake. Stemming from an international multi-centre candidate gene association study (CGAS) examining the role of polymorphisms of the blood brain barrier (BBB) efflux pump P-glycoprotein (ABCB1) for remission predictive utility (n=113); a post-doctoral study has been conducted, led by Dr Singh (results in analysis). It supports the earlier finding that the dose of antidepressant needed to remit from major depression correlates with ABCB1 genotype. Additionally, it seems another BBB transporter ABCC1 may also be relevant to antidepressant dosing. Dr Singh hopes to elucidate the pharmacogenetic keys to the BBB – a big task. His inspiration comes from seeing the reality of trial and error prescribing in clinical practice, with hopes to reduce this process and speed patient recovery through precision medicine. Dr Singh is an advisor to both government and industry groups on precision medicine, and hopes to help spearhead translation of the technology into the real world.

Determining the risk factors for musculoskeletal disorders

and conditions in the Australian population

Dr Kara Holloway, Postdoctoral Research Fellow, joined the IMPACT SRC, School of Medicine, Deakin University in July 2013. She completed a Postdoctoral qualification at The University of Adelaide in May 2013 on the history of tuberculosis, with a focus on skeletal and epidemiological methodologies. She is also an Editorial Associate for the Journal of Comparative Human Biology. Dr Holloway is currently working on assessing epidemiology and risk factors of musculoskeletal disorders using data from a number of projects. These include the Geelong Osteoporosis Study (GOS), Geelong Osteoporosis Fracture Grid and the new Ageing, Chronic Disease and Injury Study (ACDI). Her aims are to determine the risk factors associated with morbidity and mortality of musculoskeletal

disorders (such as fracture or joint replacement) as well as to provide important and useful outcomes for prevention and treatment. Kara has published five first-author manuscripts this year in good quality, peer-reviewed journals such as Calcified Tissue International, Osteoporosis International, Bone and Archives of Osteoporosis. She has another two manuscripts in the process of publication. This year, Kara’s work has been presented at many conferences, both national and international including Ballarat, Hobart, the United States and Abu Dhabi (United Arab Emirates).

Associate Professor

Ajeet B Singh, MD

Dr Kara Holloway


Inflammatory and neurotrophic biomarkers in bipolar

disorder and schizophrenia

Bipolar disorder, major depressive disorder and schizophrenia are severe and prevalent disorders, and the burden that they impose on individuals and the society is enormous, together being responsible for 50% of the global burden due to mental illnesses. One of the major reasons for that is that their pathophysiology remains relatively unknown. Lately, the search for blood markers — or biomarkers — in psychiatry has been recognised as a major endeavour in the development of a personalised approach in mental illness. Some of the primary goals of personalised medicine include establishing accurate diagnosis and predicting response to treatment. Dr Brisa Fernandes’ main research field concerns the

discovery and application of such biomarkers. She joined IMPACT SRC in 2014, and since then the quality of her contribution to the field can be seen by the analyses of inflammatory and neurotrophic biomarkers in bipolar disorder and schizophrenia, which culminated in three major publications in Molecular Psychiatry, the first ranking journal in psychiatry, as well as in BMC Medicine, a well-known journal of general medicine. The results have demonstrated that C-reactive protein and brain-derived neurotrophic factor are biomarkers of disease activity in bipolar disorder, major depressive disorder and schizophrenia, capable of assessing the severity of the symptoms in those conditions. This is being done with the ultimate goal of developing a personalised medicine for these common mental disorders. It is anticipated that the implementation of validated biomarker tests will not only improve the diagnosis and more effective treatment of persons with mental illnesses but ultimately improve prognosis and disease outcome. For continuing the pursuit of her goals, Dr Fernandes was awarded the 2015 Alfred Deakin Research Fellowship from Deakin University for two years.

Dr Brisa Fernandes


Links between anxiety and smoking

Anxiety disorders and cigarette smoking commonly occur together. Given the widely known impact of cigarette smoking as a risk factor for the development of other health issues (e.g. cardiovascular disease, lung disease etc.), it is prudent to assess the impact of smoking on the development of anxiety disorders. This project aimed to assess the association between cigarette smoking and anxiety disorder development, with a focus on how smoking may affect the expression of anxiety in the community. The project has taken data from three different population based studies: The Geelong Osteoporosis Study, the Tracing Opportunities and Problems in Childhood and Adolescence (TOPP) Study and the Norwegian Mother and Child Cohort (MoBA). In addition, the project has also incorporated a review of the literature to ascertain what particular biological pathways may underpin any observed effects. To date, the project has led to four publications in journals BMC Medicine, PLoS ONE and Brain & Behavior, with a publication under review. The results so far have demonstrated a robust association between smoking and the later development of anxiety, particularly when exposure occurs during rapid developmental phases such as gestation and adolescence. The project has now been completed. This project has provided new insights into the development of normal and pathological anxiety throughout the developmental periods, and how cigarette smoking may interfere with this process. These insights are now being used to inform anti-smoking campaigns, and also, as a template for further understanding of what influences the development of anxiety disorders.

Dr Steven Moylan


Our PhD candidates

MOODSWINGS 2.0 ONLINE INTERVENTION

Our research team are continuing their international collaboration with Stanford University, after successfully obtaining funding from the National Institute of Mental Health (NIMH) to further evaluate the MoodSwings 2.0 online self-help program for bipolar disorder (www.moodswings.net.au).

The MoodSwings program offers adjunctive psychosocial tools, information and peer support to help manage bipolar disorder. We have developed three different versions of the MoodSwings 2.0 program, and we are conducting a randomised controlled trial to determine whether there are any differences in outcomes between a discussion only version, an information version (psychoeducation), and a more intensive Cognitive Behavioural Therapy (CBT) version.

A total of 304 participants are involved in the MoodSwings 2.0 trial. Our participants are mostly from Australia and the United States, however we have participants from 27 countries in total. Follow up assessments are ongoing for this study, and we anticipate the completion of the study in 2016. EVALUATING DISCUSSION ENGAGEMENT IN AN ONLINE SELF-HELP PROGRAM FOR BIPOLAR

DISORDER (www.moodswings.net.au) There is growing evidence supporting the use of online adjunctive psychosocial interventions in the treatment of bipolar disorder. Several studies to date have included peer discussion boards, however none of these studies have specifically evaluated the role these boards play in terms of outcomes and attrition, or the influence the level of participant engagement may have on psychosocial variables. This project assesses peer discussion forums included in the MoodSwings 2.0 program (described above). This project evaluates the impact of discussion board engagement on psychosocial outcomes (such as social support, quality of life and stigma) as well as intervention adherence, and attempts to identify key differences between active and passive discussion board users. A qualitative analysis will also be conducted to determine common themes within the discussion board content.

Data collection for this study is complete, and results are anticipated in 2016. REDOX BIOLOGY AND AUTISM

This study investigated the efficacy of N-acetylcysteine (NAC) as a treatment for children with autism. Autism is a pervasive developmental disorder, comprising impairments in communication and social interaction, as well as repetitive or stereotyped behaviours or interests. Recent evidence has shown children with autism to have imbalances in their antioxidant defences, resulting in oxidative stress and cellular damage. It has been shown that the primary antioxidant in the brain, glutathione, is decreased in these children. This study investigated the effects of NAC, a glutathione precursor, on symptoms and behaviour in 102 children with autistic disorder, aged 3-10 years. The double blind, randomised trial was completed in early 2014 and found that there was no significant effect of NAC on any behavioural outcome in this sample, compared to placebo. A journal article and Kristi-Ann's doctoral thesis describing the findings are currently in preparation.

Emma Gliddon

PhD candidate

Kristi-Ann

Villagonzalo

PhD candidate

Sue Lauder

PhD candidate


Our PhD candidates continued…

A COMPARISON OF NEUROCOGNITIVE FUNCTIONING IN FIRST EPISODE MANIA PATIENTS

TREATED WITH QUETIAPINE VS. LITHIUM: A 12 MONTH FOLLOW UP

The notion of complete inter-episodic recovery in bipolar disorder has been challenged in recent years. Evidence has indicated that cognitive impairments exist during both the acute and euthymic phases of illness. However, the cognitive functioning of individuals during the early stages remains under investigated. The usual treatment for mania is a mood stabiliser such as lithium, and/or atypical antipsychotics such as quetiapine. The purpose of this study was to increase our understanding of the effects of lithium and quetiapine monotherapy on cognitive changes caused by the early stages of the disease process. An extensive cognitive assessment was conducted on 41 first episode mania participants and 21 demographically matched healthy controls, over a 12-month follow-up period. All FEM participants were aged between 15-25 years and were recruited from Orygen Youth Health and Monash Health sites. Data collection and analysis have been completed. Two

chapters from my PhD thesis have been published in peer-reviewed journals, including a systematic review on cognitive impairment in first episode mania, and the main empirical paper, which compared the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in people following a first episode of mania. In addition, two more papers on cognitive functioning in first episode mania relative healthy controls have been submitted for publication in peer-reviewed journals. I have presented my research at 5 conferences, 4 national and 1 international, and have co-authored 6 other peer-reviewed publications. TARGETING MATERNAL AND INFANT GUT HEALTH THROUGH THE PRENATAL DIET Samantha’s PhD study explores the relationship between prenatal diet quality and maternal and infant gut health. A healthy diet during pregnancy is recommended for maternal health and infant development. The gut microbiome is modifiable by diet; and emerging evidence indicates that early life gut health is important for brain and immune system development and function. Samantha’s PhD hypothesises that prenatal diet quality will be associated with gut health in mothers and infants. In 2016, she will undertake a randomized controlled trial to evaluate the potential for a prenatal dietary intervention targeting gut health to influence microbial diversity and abundance, and short chain fatty acids in mothers and infants after birth. The results may be relevant to future research aiming to target the microbiome as a potential risk factor for non-communicable diseases.

Samantha is undertaking the first year of her PhD, having started in February 2015 with IMPACT SRC. She is based at the Murdoch Children’s Research Institute in Melbourne hosted within the Early Life Epigenetics team. Samantha comes to her PhD with prior research experience, having worked as a research fellow with the Deakin Centre for Rural Emergency Medicine. She holds a Master of Human Nutrition from Deakin University (2014), and a Bachelor of Computer Science from Wollongong University (2004).

Rothanthi Daglas

PhD candidate

Samantha Dawson

PhD candidate



PERSONALITY DISORDERS IN THE COMMUNITY

Individuals with personality disorders, suffer from a range of longstanding difficulties with interpersonal relating, self-organization, emotional instability, and problematic behaviours. Yet the prevalence of those living with personality disorder in Australian is not well understood. Just under half of all people with psychiatric disorders also have a co-existing chronic physical illness. However, personality disorder and the associated risks for physical health conditions have not been thoroughly investigated.

From a public health perspective it is essential to plan for and anticipate the health care needs of the Australian population, and for bridging the gap between physical and psychiatric health systems. However the current mental and medical help-seeking behaviours of Australians living with personality disorder are largely unknown. The aim of this project was to investigate the prevalence of personality disorders in Australian women participating in the Geelong Osteoporosis Study (GOS) as well as the

associations with physical health conditions and utilisation of mental and physical health-related services.

Our team has now collected data from the female arm of the GOS. This project identified that approximately one in five women had one or more personality disorders in the community, with significant mental and physical comorbidity. Individuals with personality disorders also utilised a greater number of mental and physical health-related services than women without these disorders. Recognizing the disability attributable to personality disorders in the community is essential for anticipating and planning healthcare needs. DESCRIBING THE DISEASE BURDEN AND HEALTH SERVICE UTILISATION ASSOCIATED WITH

DIABETES MELLITUS AND CANCER IN WESTERN VICTORIA

The current trends of fertility, life expectancy, migration and the expected growth in regional populations will contribute to an increased need for chronic disease-related health services in these areas in the future. In order to inform policy and adequately plan improved delivery of health services, it is vital to establish the health service needs of the population. Such information could assist in developing innovative models of care to address the health service needs of an ageing population as well as reducing the demand by implementing effective prevention strategies. The Ageing, Chronic Disease and Injury (ACDI) study was launched in 2015 to address this need in western Victoria.

My doctoral project forms part of the ACDI study and aims at describing the burden of diabetes and cancer in western Victoria and the associated health service utilisation. Data will be obtained from chronic disease registers (Victorian Cancer Registry, National Diabetes Services Scheme etc.) and estimates of burden (incidence, prevalence and mortality) will be reported by age, sex and location of residence. Associations between disease burden, health service use and socioeconomic status, remoteness and accessibility to health services will be investigated.

Currently, a manuscript describing socio-demographic characteristics of the region is under review. Furthermore, an abstract describing cancer incidence rates in western Victoria was accepted at the Western Alliance Academic Health Science Centre symposium and I had the opportunity to present my findings there. The process of acquiring data from the National Diabetes Services Scheme, Medicare Australia and hospital admission records will continue over the next a few months and the results will be published in peer-reviewed journals.

Shae Quirk

PhD candidate

Muhammad Sajjad

PhD candidate



THE USE OF MACHINE LEARNING AND DATA MINING IN THE DEVELOPMENT OF A CLINICAL RISK

INDEX FOR DEPRESSION

In Australia, depressive and anxiety disorders are increasingly common, seemingly affecting people of younger and younger ages. The impact of these psychological disorders on both the individual and society is far-reaching; with a detrimental impact upon the psychological, social and economic elements of everyday life. The aim of this research study is to use machine learning and data mining techniques to identify risk factors for depression so as to develop a clinically useful tool for predicting depression.

A theoretical large-scale data mining techniques using machine learning algorithms have promise in the analysis of large epidemiological datasets. This year I developed a hybrid methodology, amalgamating multiple imputation, a machine learning boosted regression algorithm and logistic regression, to identify key biomarkers associated with depression in a large epidemiological study. The method was found to be a useful tool for

detecting three biomarkers associated with depression for future hypothesis generation: red cell distribution width, serum glucose and total bilirubin. I presented this research at the Oceania Stata Users statistical group, as a poster at the Society for Mental Health Research (SMHR) 2015 Conference and the manuscript is currently being reviewed for publication. My current investigation involves the utilisation of machine learning to identify lifestyle clusters associated with depression to be integrated in the final depression risk index. ANTECEDENTS OF AGED CARE SERVICE UTILISATION IN A SAMPLE OF OLDER AUSTRALIANS:

PROSPECTIVE DATA LINKAGE USING GOVERNMENT ADMINISTRATIVE RECORDS

The purpose of my PhD project is to develop risk profiles for aged care service utilisation among older men and women living in the community. In this project, I am investigating clinical risk factors and lifestyle-related exposures that increase the risk for homecare services and residential aged care. The study method involves data linkage between information collected over a period of twenty years from participants enrolled in the Geelong Osteoporosis Study (GOS) and government administrative records. The burgeoning older population in Australia poses a significant challenge to the aged care system, and avoiding or

delaying the use of aged care services is likely to have downstream social and economic benefits. This research will provide a sound evidence base that will inform public health messages about healthy ageing and maintaining independence. DYSGLYCAEMIA IN WOMEN

Lelia was enrolled as a PhD candidate with the IMPACT SRC team in August 2014. She joins our team from Brazil after completing a Bachelor of Nursing and a Masters in Nursing, with a focus on diabetes. She has also worked in the Public Health sector as a registered nurse for a number of years.

Her research interests include diabetes, gestational diabetes, obesity and metabolic syndrome. Her PhD project, supervised by Professor Julie Pasco, Dr Mark Kotowicz and Dr Kara Holloway, is focussed on diabetes and pre-diabetes in female participants of the Geelong Osteoporosis Study. She will be describing the epidemiology of diabetes and pre-diabetes in the Barwon Statistical Division. In addition, she will also be determining risk factors for developing diabetes as well as investigating associations between diabetes and mental health, healthcare utilisation, fractures and mortality.

Haslinda Gould

PhD candidate

Lelia de Abreu

PhD candidate

Joanna Dipnall

PhD candidate



BIOLOGICAL PATHWAYS THAT MEDIATE THE LINK BETWEEN DIET AND DEPRESSION

The relationship between diet and mental health has now been demonstrated across age groups and various geographic locations; however, there is still a lack of understanding as to which biological pathways are directly and indirectly involved. There are several systems that are known to be associated with both dietary patterns and mood, and are proposed to mediate this relationship. Recent literature has pointed to the inflammatory nature of some common mental disorders, and there is evidence that the origin of this inflammation, at least in part, may be in the gut.

The colonisation of the gut microbiome begins in very early life, and its composition is influenced by genetic, environmental and lifestyle factors. While there seems to be a ‘core’ composition of the gut microbiome that is

passed on from our mothers and determined by early life factors, a proportion of this bacterial population is modifiable. The composition can be modified by factors such as stress and antibiotic use, however the largest and most lasting alterations in gut microbiome result from habitual diet. It’s understood that poor quality ‘Western’ diets are associated with inflammation. New investigations also demonstrate that poor quality diets may be linked to poor gut bacteria diversity, and compromised function of the epithelial mucosal barrier, often termed ‘Leaky Gut’.

‘Leaky Gut’ occurs when bacterial molecules exit the digestive system and enter the blood stream; this evokes an immuno-inflammatory response. This chronic activation of the immune and inflammatory systems is a risk factor for a variety of disorders, including common mental disorders. This projects aims to investigate the mediating role of these biological systems in the diet-depression association. The Dietary Inflammatory Index (DII), a new measure developed by our collaborators in the US, is used to convert complex dietary information to a score that estimates the inflammatory potential of a diet. This project will be using the DII, in combination with and array of inflammatory, gut health & stress biomarkers to elucidate important mediating biological mechanisms. By understanding the influence of changes in diet and/or mood on a variety of inflammatory biomarkers, including those linked to the health of the gut, we hope to better understand and identify some of the possible mechanisms to guide the development of targeted dietary prevention or intervention strategies. DISSOCIATION AND CHANGES IN THE PERCEPTION OF TIME

This doctoral study aims to combine a number of research methods to better understand how the perception of time is altered in psychiatric disease. It has involved an ongoing collaboration between Barwon Health, Barwon Medical Imaging, the University of Melbourne and the Department of Physiology, Development and Neuroscience at the University of Cambridge. In particular, the research focuses upon changes in the perception of the “flow” of time and ordering of events.

Over the last year, reports have been prepared for submission regarding the fMRI and behavioural findings of the research. Most recently we have found evidence that patients with bipolar disorder exhibit changes in temporal perception and timing performance which accompany mood alterations. In particular, manic symptoms, as measured by the Young Mania Rating Scale, correlated with increased rates of misordered temporal judgements.

These findings continue the process of unravelling the neurological foundations of time perception. Our studies have shown that changes in time perception accompany mood changes in bipolar disorder and that we can measure the changes in brain activity that accompany specific time estimation measures. Importantly there is a strong linkage between time perception and dissociative symptoms which we hope to explore further in different populations with mental illness.

Sarah Dash

PhD candidate

Dr Frank

Giorlando

PhD candidate



GESTATIONAL VITAMIN D AND DEVELOPMENT IN OFFSPRING

A significant number of Australian women, including those of reproductive age, have low vitamin D levels. Gestational vitamin D insufficiency is a cause for concern, not only for the maternal health, but because it also exposes the offspring to insufficiency during potentially critical stages of development. It is known that vitamin D deficiency in infancy and childhood affects bone health and muscle function. It is thus an important public health issue to determine whether gestational vitamin D levels impact upon musculoskeletal and other areas of health in the offspring.

The Vitamin D in Pregnancy (VIP) study’s initial findings showed impaired growth and development in offspring born to vitamin D deficient mothers. The study is currently in its final stages of recruitment for its 10 year follow-up phase and aims to determine whether these observed

effects are transient or maintained into childhood.

Results of other observational studies have, to date, been conflicting and currently much conjecture exists with regards to optimal vitamin D levels during pregnancy for ideal offspring development. It is hoped that results from this study will add to the growing evidence base and used to formulate an evidence-based healthcare approach to vitamin D recommendations throughout pregnancy. THE WORLD HEALTH ORGANISATION DEFINES HEALTH LITERACY AS ‘THE COGNITIVE AND

SOCIAL SKILLS WHICH DETERMINE THE MOTIVATION AND ABILITY OF INDIVIDUALS TO GAIN

ACCESS TO, UNDERSTAND AND USE INFORMATION

It has been estimated that up to a quarter of the Australian population may have sub-optimal health literacy; this is important as a there is a growing body of evidence linking low health literacy with a wide range of poor health outcomes.

While there is a great deal of evidence regarding the role of health literacy in the prevention and management of a number of chronic conditions, currently very little data is available relating to health literacy and musculoskeletal conditions. This project aims to address the current knowledge gap using data from the Geelong Osteoporosis Study (GOS) and the Vitamin D in Pregnancy (VIP) Study.

Health literacy measures are currently being undertaken in both cohorts using the Health Literacy Questionnaire (HLQ), which generates detailed health literacy profiles assessing participants across a range of skills and abilities.

Participant health literacy profiles will be analysed, alongside data already collected (including osteoporosis related clinical measures, health service utilisation and lifestyle information) in order to understand the health literacy strengths and weaknesses of those at greatest risk of developing osteoporosis.

With a better understanding of the health literacy strengths and weaknesses of those at greatest risk we will be better placed to develop interventions that are likely to be of most value in reaching those in greatest need.

Natalie Hyde

PhD candidate

Sarah Hosking

PhD candidate



BONE MATERIAL STRENGTH INDEX: A NEW METHOD FOR DETERMINING THE MATERIAL

PROPERTIES OF BONE

As people get older, their bones become weaker and more susceptible to fracture. Current techniques used for estimating the strength of the bone usually involve assessing bone mineral density (BMD). However, BMD measurements alone do not elucidate the risk of fracture because the largest absolute number of osteoporotic fractures occurs in people with a moderate reduction in bone mass (osteopenia). Several other clinical factors such as genetics, history of fracture, cardiovascular diseases, smoking, obesity, alcohol consumption, muscle mass, physical activity and medications (such as glucocorticoids) can also contribute independently to the risk of fracture. Consequently, there is a need to directly assess the ability of the bone to resist fracture.

My project involves the use of a device known as ‘Osteoprobe’. It is a novel, hand-held device designed for clinical measurements of bone material properties in situ. The Osteoprobe is a reference point indentation instrument that quantifies the ability of bone to resist the growth of cracks and this is expressed as the bone material strength index (BMSi). This material property of bone, which is a component of

bone quality, should be useful for determining bone strength and ability to resist fracture.

I will be measuring BMSi in a cohort of men as part of their 10-year follow-up assessment. Age-specific reference ranges for BMSi for men will be generated and correlations between the BMSi and other indices of bone quality and strength will be quantified. The relationships between the BMSi, health behaviours, socio-demographics and fracture risk will also be explored.

The results of this study may lead to new ways of exploring how specific lifestyle factors and pharmaceutical interventions impact the mechanical properties of bone. Using a novel instrument which can assess the susceptibility of bone to fracture, we can begin to study how physical activity, smoking, medications, diet and other lifestyle factors can contribute to bone strength. Furthermore, clinicians will be able to use the Osteoprobe to make decisions about the best pharmaceutical treatments for their patients.

Ongoing funding for 2015 1. NHMRC Established Career Fellowship. APP1059660. Novel therapies, risk pathways

and prevention of mood disorders. Berk M. (GNT1064272). $822,925. 2014-2018. 2. NHMRC Career Development Fellowship (APP1064272). Psychiatric disorders,

psychotropic agents and bone health: From bench top to bedside. Williams L. $404,884. 2014-2018.

3. NHMRC Project Grant (APP1078928). Gene Expression Signature Technology to

Repurpose Drugs for Bipolar Disorder. Walder K, Berk M, Leboyer M. : $467,203. 2015-2017.

4. NHMRC Project Grant (APP1081901). ASPREE-D; Aspirin in the prevention of depression in the elderly. CIA: Berk M, McNeil J, Neilson M, Shah R, Woods R, Mohebbi M. $767,593. 2015-2018.

5. Alfred Deakin Postdoctoral Research Fellowship. Investigation of the psychosocial and socioeconomic disparities in osteoporosis and the uptake of osteoporosis-related healthcare using a multi-disciplinary approach. Brennan-Olsen S. 2015-2016.

Pamela Rufus

PhD candidate


Ongoing funding 2015 continued…

6. Simons Foundation Autism Research Initiative - SFARI. Pilot Grant. Efficacy of N-Acetyl

Cysteine in Autism. 2014-2015. Berk M, Dodd S, Dean P, Gray L, Tonge B. $244,256. 7. AstraZeneca D1443C00002: Neuroprotective Properties of Quetiapine versus Lithium

in a First Episode Mania Cohort: 12-month Neuroanatomical, Neurochemical and Neuro-cognitive Effects and Preliminary Data of Prophylactic Properties. Berk M, Hallam K, Lucas N, Macneil C, Hasty M, Kader L, O’Regan M, Callaly T, Conus P, Damodoran S, Brotchie P, Pantelis C, Yucel M, McGorry PD. $1.68 million.

8. Stanley #14T-007. The efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for the treatment of Schizophrenia: A double-blind, randomized, placebo-controlled trial. Berk M, McGrath J, Dean O, Dodd S, Cotton S. Three years. 2015-2017. US$899,398.

9. Western Alliance. Chronic disease, injury and ageing in Western Victoria: opportunities to improve health delivery. Pasco JA, Kotowicz MA, Livingston T, Khasraw M, Hakkennes S, Dunning T, Brumby S, Page R, Pedler D, Sutherland A, Venkatesh S. 2015-16. $100,000.

Successful grants 2015

1. ASBDD/Servier depression research grant. Dr Olivia Dean, post-doctoral research fellow. $30,000.

2. ASBDD/Lundbeck 2015 Neuroscience Scholarship. Melanie Ashton, PhD candidate.

$30,000. 3. ANZBMS Travel Grants. Dr Kara L. Holloway, post-doctoral research fellow. $250. 4. Alfred Deakin Post-doctoral Research Fellowships. Dr Kara Holloway, Dr Brisa

Fernandes, post-doctoral research fellows. ($78,146 in 2016, $80,967 in 2017, $10,000 project funding).

5. National Natural Science Foundation of China. (NO:81560235). Title: The study on the

pathogenesis of endoplasmic reticulum stress in the impaired regional cerebral blood flow on major depressive disorder. Grant recipient?? Is it 2015??RMB 465000 (Chinese Yen = AUD$103,424).

Internal IMPACT SRC grants:

6. Epigenetic pathways: Implications for social disparities in osteoporotic fracture? Dr Sharon Brennan-Olsen, post-doctoral research fellow. $4,000.

7. Bone material strength index: a new method for determining material properties of

bone. Dr Kara L. Holloway, post-doctoral research fellow. $10,000. 8. The efficacy of adjunctive Garcinia mangostana Linn for bipolar depression: A 6-

month double-blind, randomised, placebo controlled trial. Dr Olivia Dean, post-doctoral research fellow. $20,000.


Internal IMPACT SRC grants continued…

9. The epidemiology burden and comorbidity of personality disorders in Australia. Dr Lana Williams, post-doctoral research fellow. $20,000.

10. M-CSF and the risk for fracture. Prof Julie Pasco. $10,000.

11. Minocycline as an adjunctive treatment for unipolar depression. Dr Olivia Dean, post-

doctoral research fellow. $17,049. 12. Bone material strength index: a new method for determining material properties of

bone. Dr Kara Holloway , post-doctoral research fellow. $3,500.

Awards 2015

1. Sarah Dash, PhD candidate was awarded a Top-Up Scholarship, by the Collaborative Research Centre for Mental Health (CRC), 2015.

2. Dr Brisa Fernandes, post-doctoral research fellow, won Best Early-Career Researcher Poster at the 2015 Australasian Society for Bipolar and Depressive Disorders (ASBDD) conference.

3. Melanie Ashton, PhD candidate, was awarded the 2015 ASBDD/Lundbeck Neuroscience Scholarship.

4. Dr Olivia Dean, post-doctoral research fellow, was awarded the 2015 ASBDD/Servier Depression Research Grant.

5. Sue Lauder, PhD candidate, won the Best Early-Career Researcher Oral Presentation at the 2015 ASBDD conference.

6. Dr Sharon Brennan-Olsen, post-doctoral research fellow, was awarded the 2015 Professor Philip Sambrook Award at the Australian and New Zealand Bone and Mineral Society conference (ANZBMS).

7. Dr Lana Williams, post-doctoral research fellow, was awarded a NHMRC project grant for her work investigating bone health in bipolar disorder.

8. Emma Gliddon, PhD candidate, was awarded the inaugural Past District Governor Geoff Betts Early Mental Health Researcher Award from the Rotary Club of Geelong, as well as a Grant-in-Aid for the 2015 Society for Mental Health Research conference.

9. Dr Shae Quirk, post-doctoral research fellow, was awarded the Faculty of Health HDR Publication Award for her thesis submitted in 2015.

10. Prof Michael Berk was listed as an ICI highly cited researcher and won the Brain and Behaviour Foundation Colvin Award.

11. Dr Sharon Brennan-Olsen, post-doctoral research fellow, received a NHMRC Career

Development Fellowship.

12. A/Prof Felice Jacka, post-doctoral research fellow, received a NHMRC Career Development Fellowship.

13. Aswin Ratheesh, PhD candidate, was awarded an early career researcher oral communication award from the Australasian Society of Bipolar and Depressive Disorders conference.


International collaborations with IMPACT SRC

Universidad Complutense, Madrid, Spain. Université Paris-Est, Paris, France.

Stanford University, CA, United States. Universidad de Antioquia, Medellín, Colombia.

Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Universidade Estadual de Londrina, Paraná, Brazil.

University of Toronto, ON, Canada. University of Bergen, Norway.

Hospital Santa Maria, Lisbon, Portugal. Shiraz University of Medical Sciences, Shiraz, Iran.

Harvard Medical School, MA, United States. University of Manitoba, Winnipeg, Canada.

McGill University, Montreal, Quebec, Canada.

University of Cantabria, Santander, Spain.

Loyola University Chicago, Maywood, IL, USA.

Edward Hines Jr VA Hospital, Hines, IL, USA.

University of Glasgow, Glasgow, Scotland. Chulalongkorn University, Thailand.

University of Eastern Finland. Norwegian University of Science and Technology

Guiyan Medical University, China Norwegian Institute of Public Health.

Oxford University. Cambridge University. University of Barcelona. Lausanne University Hospital. University College Cork. University of Glasgow.

National collaborations with IMPACT SRC

City of Greater Geelong, Geelong. G21 Alliance, Geelong.

The University of Melbourne, Parkville. Florey Institute of Neuroscience and Mental Health.

Orygen, The National Centre of Excellence in Youth Mental Health.

Monash University, Clayton.

Australian Catholic University, Melbourne. Sir Charles Gairdner Hospital, Nedlands, Western Australia.

The University of Western Australia, Nedlands, Western Australia.

The University of Sydney, Sydney.

Menzies Research Institute, Hobart, Tasmania.

The University of Queensland, St Lucia.

Queensland University of Technology, Brisbane.

University of Queensland Diamantina Institute, Woolloongabba.

James Cook University, Townsville. Murdoch Children’s Research Institute, Parkville.

Swinburne University, Melbourne. University of New South Wales, Sydney.

The Black Dog Institute, Sydney. The CADE clinic, Sydney.

The Brain and Mind Research Institute, Sydney.

QIMR Berghofer Medical Research Institute, Brisbane.

Australian National University, Canberra. The Australian Institute for Musculoskeletal Sciences, Melbourne.


Publications 2015 1. Lopresti A, Jacka FN. Diet and bipolar disorder: a review of its relationship and

potential therapeutic mechanisms of action Journal of Alternative and Complementary Medicine (2015).

2. Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry World Psychiatry 14:3 (2015) IF=14.22.

3. Jacka FN, Cherbuin N, Anstey KJ, Sachdev P Butterworth P. Western diet is associated with a smaller hippocampus: a longitudinal investigation BMC Med (2015) 13:215.

4. Opie RS, Itsiopoulos C, Parletta N, Sanchez-Villegas A, Akbaraly TN, Ruusunen A, Jacka FN. Dietary recommendations for the prevention of depression. Nutritional Neuroscience (published online Aug 30 2015).

5. Kingsbury M, Dupuis G, Jacka FN, Roy-Gagnon MA, McMartin SE, Colman I. Associations between fruit and vegetable consumption and depressive symptoms: evidence from a national Canadian longitudinal survey. Journal of Epidemiology and Community Health (published on August 26, 2015 as 10.1136/jech-2015-205858).

6. Hoare E, Millar L, Fuller-Tyszkiewicz M, Skouteris H, Nichols M, Jacka FN, Swinburn B, Chikwendu C, Terry J, Allender S. Higher odds of depressive symptomatology associated with obesity risk in Australian adolescents Obes Res Clin Prac (2015) published online June 04.

7. Opie RS, Segal L, Jacka FN, Nicholls L, Dash S, Pizzinga J, Itsiopoulos C. Assessing healthy diet affordability in a cohort with major depressive disorders (2015) J Public Health Epidemiol Vol.7(5), pp. 159-169.

8. Baskin R, Hill, B, Jacka, FN, O'Neil A, & Skouteris H. The Association between Diet Quality and Mental Health during the Perinatal Period: A systematic Review. Appetite (2015) 91:41-47.

9. Williams LJ, Pasco JA, Stuart AL, Jacka FN, Brennan SL, Dobbins AG, Honkanen R, Koivumaa-Honkanen H, Rauma PH and Berk M. Psychiatric disorders, psychotropic medication use and falls among women: an observational study BMC Psychiatry (2015) 15:75.

10. O'Neil A, Jacka FN, Quirk SE, Cocker F, Barr Taylor C, Oldenburg B and Berk M. A shared framework for the Common Mental Disorders and Non-Communicable Disease: key considerations for disease prevention and control BMC Psychiatry 2015 Feb 5;15(1):15.

11. Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. Nutritional Medicine as Mainstream in Psychiatry. Lancet Psychiatry 2015; 2: 271–74.

12. Jacka FN, Cherbuin N, Anstey KJ, Butterworth P. Does reverse causality explain the relationship between diet and depression? Journal of Affective Disorders (2015) 175: 248–250.

13. Dash S, Clarke G, Berk M, Jacka FN. The Gut Microbiome and Diet in Psychiatry: Focus on Depression Curr Opin Psychiatry. 2015 Jan;28(1):1-6.

14. Abimanyi-Ochom J, Watts JJ, Borgstrom F, Nicholson GC, Shore-Lorenti C, Stuart AL, Zhang Y, Iuliano S, Seeman E, Prince R, March L, Cross M, Winzenberg T, Laslett LL, Duque G, Ebeling P, Sanders KM. Changes in Quality of life associated with fragility fractures: AusICUROS (Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study). Osteoporosis International, Jun;26(6):1781-90. doi: 10.1007/s00198-015-3088-z. Epub 2015 Mar 20.


Publications 2015 continued…

15. Scott D, McLaughlin P, Nicholson GC, Ebeling PR, Stuart AL, Kay D, Sanders KM. Changes in gait performance are associated with incident falls over four years in community-dwelling older women at high risk of fracture. Age and Ageing Mar 2015;44(2):287-93.

16. Sanders KM, Stuart AL, Scott D, Kotowicz MA, Nicholson GC. Validity of 12-month falls recall in community-dwelling older women participating in a clinical trial. International Journal of Endocrinology. 2015: doi: 10.1155/2015/210527.

17. Brennan SL, Holloway KL, Williams LJ, Kotowicz MA, Bucki-Smith G, Moloney DJ, Dobbins AG, Timney EN, Pasco JA. The social gradient of fractures in men and women: Data from the Geelong Osteoporosis Study Fracture Grid. Osteoporos Int, 2015, 26:1351-1359.

18. Brennan SL, Yan L, Lix LM, Morin SN, Majumdar SR, Leslie WD. Sex and age-specific associations between income and incident major osteoporotic fractures in Canadian men and women: A population-based analysis. Osteoporos Int, 2015, 26:59-65. doi: 10.1007/s00198-014-2914-z.

19. Brennan SL, Quirk SE, Hosking SM, Kotowicz MA, Holloway KL, Moloney DJ, Dobbins AG, Pasco JA. Is there an interaction between socioeconomic status and FRAX 10-year fracture probability determined with vs. without the use of bone density measures? Data from the Geelong Osteoporosis Study female cohort. Calc Tiss Int, 2015, 96:138-144. doi: 10.1007/s00223-014-9946-4.

20. Brennan-Olsen SL, Williams LJ, Holloway KL, Hosking SM, Stuart AL, Dobbins AG, Pasco JA. Small area-level socioeconomic status and all-cause mortality within 10 years: Data from the Geelong Osteoporosis Study. Prev Med Reports, 2015, 2:505-511.

21. Leslie WD, Brennan-Olsen SL, Morin SN, Lix LM. Fracture prediction from repeat BMD measurements in routine clinical practice. Osteoporosis International. Accepted 10/7/2015.

22. Holloway KL, Brennan SL, Kotowicz MA, Bucki-Smith G, Dobbins AG, Timney EN, Williams LJ, Pasco JA. Age- and sex-related patterns of first fracture and fracture prevalence. Calcified Tissue International 2015; 96(1): 38-44. doi: 10.1007/s00223-014-9936-6.

23. Holloway KL, Brennan SL, Kotowicz MA, Bucki-Smith G, Timney EN, Dobbins AG, Williams LJ and Pasco JA. 2015. Prior fracture as a risk factor for future fracture in an Australian cohort. Osteoporosis International, 26 (2): 629-635, DOI: 10.1007/s00198-014-2897-9.

24. Pasco JA, Lane SE, Brennan SL, Holloway KL, Timney EN, Bucki-Smith G, Dobbins AG, Williams LJ, Hyde NK, Kotowicz MA. The epidemiology of incident fracture from cradle to senescence. Accepted Calcified Tissue International and Musculoskeletal Research 13/8/2015.

25. Holloway KL, Henry MJ, Brennan-Olsen SL, et al. 2015. Non-hip and non-vertebral fractures: the neglected fracture sites. Osteoporosis International. doi: 10.1007/s00198-015-3322-8.

26. Holloway KL, Brennan-Olsen SL, Kotowicz MA, Moloney DJ, Bucki-Smith G, Morse AG, Timney EN, Dobbins AG, Pasco JA. Humeral fractures in south-eastern Australia: epidemiology and risk factors. Calcified Tissue International July 2015; 97(5):453-465. doi 10.1007/s00223-015-0039-9.

27. Holloway KL, Moloney DJ, Brennan-Olsen SL, Kotowicz MA, Bucki-Smith G, Morse AG, Timney EN, Dobbins AG, Hyde NK, Pasco JA. Carpal and scaphoid fracture incidence in south-eastern Australia: an epidemiologic study. Archives of Osteoporosis 2015; 10(1): 215. doi: 10.1007/s11657-015-0215-6.

28. Stuart A, Williams LJ, Brennan SL, Kotowicz MA, Pasco JA. Poor agreement between self-reported diagnosis and bone mineral density results in the identification of osteoporosis. J Clinic Densitom, 2015, 18(1):13-16.



29. Hosking SM, Dobbins AG, Pasco JA, Brennan SL. Knowledge change regarding osteoporosis prevention: Translating recommended guidelines into user-friendly messages for the community. BMC Research Notes, 2015, 8:33. doi: 10.1186/s13104-015-0985-3.

30. Holloway KL, Kotowicz MA, Lane SE, Brennan SL, Pasco JA. FRAX (Aus) and falls risk: Association in men and women. Bone 2015; 76: 1-4. doi: 10.1016/j.bone.2015.03.004.

31. Pasco JA, Berk M, Williams LJ, Brennan-Olsen SL, Jacka FN. Milk consumption and the risk for incident MDD. Psychotherapy and Psychosomatics, 2015, 84(6):384-386

32. Williams LJ, Pasco JA, Stuart AL, Jacka FN, Brennan SL, Dobbins AG, Honkanen R, Koivumaa-Honkanen H, Rauma P, Berk M. Psychiatric disorders, psychotropic medical use and falls among women; an observational study. BMC Psychiatry, 2015, 15(1):75.

33. Harding J, Shaw J, Anstey KJ, Adams R, Balkau B, Brennan-Olsen SL, Briffa T, Davis TM, Davis WA, Dobson A, Flicker L, Giles G, Grant J, Huxley R, Knuiman M, Luszcz M, MacInnis RJ, Mitchell P, Pasco JA, Reid C, Simmons D, Simons L, Tonkin A, Woodward M, Peeters A, Magliano DJ. Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 Australian cohorts. International Journal of Cancer 2015;137(7):1699-1708. doi: 10.1002/ijc.29529.

34. Quirk SE, El-Gabalawy R, Brennan SL, Bolton J, Sareen J, Berk M, Chanen A, Pasco JA, Williams LJ. Personality disorders and physical comorbidities in adults from the United States: data from the National Epidemiologic Survey on Alcohol and Related Conditions. Social Psychiatry and Psychiatric Epidemiology 2015;50(5):807-820. doi: 10.1007/s00127-014-0974-1.

35. Pasco JA, Holloway KL, Brennan-Olsen SL, Moloney DJ, Kotowicz MA. Muscle strength and areal bone mineral density at the hip in women: a cross-sectional study BMC Musculoskeletal Disorders, 2015; 16:124. doi:10.1186/s12891-015-0586-2.

36. Pasco JA, Williams LJ, Jacka FN, Stupka N, Brennan-Olsen SL, Holloway KL, Berk M. Sarcopenia and the common mental disorders: A potential regulatory role of skeletal muscle on brain function? Curr Osteo Reports, 2015; 13(5): 351-357. DOI: 10.1007/s11914-015-0279-7.

37. Quirk SE, Berk M, Chanen AM, Koivumaa-Honkanen H, Brennan-Olsen SL, Pasco JA, Williams LJ. Population prevalence of personality disorder and associations with physical health comorbidities and health care service utilization: A review. Personality Disorders 2015 Oct 12 [Epub ahead of print].

38. Hayley AC, Williams LJ, Kennedy GA, Holloway KL, Berk M, Brennan-Olsen SL, Kotowicz MA, Pasco JA. Excessive daytime sleepiness and falls among older adults: cross-sectional examination of a population-based sample. BMC Geriatrics, 2015; 15:74, doi: 10.1186/s12877-015-0068-2.

39. Harding JL, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Brennan-Olsen SL, Briffa T, Davis TME, Davis WA, Dobson A, Giles GG, Grant J, Huxley R, Knuiman M, Luszcz M, Mitchell P, Pasco JA, Reid CM, Simmons D, Simons L, Taylor AW, Tonkin A, Woodward M, Shae JE, Magliano DJ. Hypertension, anti-hypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. Journal of Hypertension IN PRESS (accepted 3/09/2015).

40. Butterworth PA, Menz HB, Urquhart DM, Cicuttini FM, Landorf KB, Pasco JA, Brennan SL, Wluka AE. Fat mass is associated with foot pain in adult males: The Geelong Osteoporosis Study. Rheumatology. Accepted September 16, 2015.



41. Gliddon E, Lauder S, Berk L, Cosgrove V, Grimm D, Dodd S, Suppes T, Berk M, 2015. Evaluating discussion board engagement in the MoodSwings online self-help program from bipolar disorder: protocol for an observational prospective cohort study. BMC Psychiatry (accepted for publication).

42. Van Rheenen TE, Davidson, SK, Giorlando F, Gliddon E, Dean O. M. Fostering early and mid-career research in affective disorders. Australian & New Zealand Journal of Psychiatry, 2015 2-1.

43. Lauder S, Chester A, Castle D, Dodd S, Gliddon E, Berk L, Chamberlain J, Klein B, Gilbert M, Austin DW, Berk M, 2015. A randomised head to head trial of MoodSwings.net.au: An internet based self-help program for bipolar disorder. Journal of Affective Disorders. 171, 13-21.

44. Gliddon E. Breaking down barriers: Online self-help for bipolar disorder. Mental Health Matters magazine. 2015; 2 (1), 41-42.

45. Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean O, Nardin P, Goncalves CA, Berk M. C-Reactive Protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Molecular Psychiatry (Accepted 27th May 2015 –published online 14/7/2015).

46. Fernandes BD, Dean OM, Dodd S, Malhi GS, Berk M (2015) N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. Journal of Clinical Psychiatry (Accepted 19th May 2015).

47. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev. 2015:55:294-321.

48. Nabavi SF, Dean OM, Turner A, Sureda A, Daglia M, Nabavi SM. Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols? Current Medicinal Chemistry (2015); 22(3):343-5.

49. Van Rheenen TE, Davidson SK, Giorlando F, Gliddon E, Dean OM. Fostering Early-Mid Career Research in Affective Disorders: The Australasian Society of Bipolar and Depressive Disorders Early-Mid Career Researcher Sub-Committee. ANZJP (2015); 49(4):387-8.

50. Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J. N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. Clinical Psychopharmacology and Neuroscience (2015); 13(1):12-24.

51. Dean OM, Turner A, Malhi GS, Ng C, Cotton S, Dodd S, Sarris J, Samuni Y , Tanious M, Dowling N, Waterdrinker A, Smith D, Berk M. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira de Psiquiatria. (2015); 37(1):3-12.

52. Thomson D, Berk M, Dodd S, Rapado-Castro M, Quirk SE, Ellegaard PK, Berk L, Dean OM. Tobacco use in bipolar disorder. Clinical Psychopharmacology and Neuroscience. (2015); 13(1):1-11.

53. Dodd S. Novel therapeutic targets for bipolar disorder. In Treatment-resistant mood disorders. Chapter 14. pps. 147-156. Editors: Andre F. Carvalho & Roger S. McIntyre. Oxford University Press. 2015 ISBN: 978-0-19-870799-8.

54. Dipnall J, Pasco JA, Meyer D, Berk M, Williams LJ, Dodd S, Jacka FN. The association between dietary patterns, diabetes and depression. Journal of Affective Disorders 2015; 174: 215–224.



55. Odebrecht Vargas Nunes S, Pizzo de Castro MR, Gastaldello Moreira E, Guembarovski RL, Sabbatini Barbosa D, Odebrecht Vargas H, Piccoli de Melo LG, Bortolasci CC, Ehara Watanabe MA, Dodd S, Berk M, Maes M. Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. Neuroscience Letters 2015; 585:132–137.

56. Prado E, Maes M, Gustavo Piccoli L, Baracat M, Sabattini Barbosa D, Franco O, Dodd S, Berk M, Odebrecht Vargas Nunes S. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Report 2015; 20(5): 215-222.

57. Bauer M, Glenn T, Alda M, A. Andreassen O, Angelopoulos E, Ardau R, Baethge C, Bauer R, Baune BT, Bellivier F, Belmaker RH, Berk M, Bjella TD, Bossini L, Bersudsky Y, Yat Wo Cheung E, Conell J, Del Zompo M, Dodd S, Etain B, Fagiolini A, Frye MA, Fountoulakis KN, Garneau-Fournier J, Gonzalez-Pinto A, Gottlieb JF, Harima H, Hassel S, Henry C, Iacovides A, Isometsä ET, Kapczinski F, Kliwicki S, König B, Krogh R, Kunz M, Lafer B, Larsen ER, Lewitzka U, Lopez-Jaramillo C, MacQueen G, Manchia M, Marsh W, Martinez-Cengotitabengoa M, Melle I, Monteith S, Morken G, Munoz R, Nery FG, O'Donovan C, Osher Y, Pfennig A, Quiroz D, Ramesar R, Rasgon N, Reif A, Ritter P, Rybakowski JK, Sagduyu K, Ângela Miranda- Scippa A, Severus E, Simhandl C, Stein DJ, Strejilevich S, Hatim Sulaiman A, Suominen K, Tagata H, Tatebayashi Y, Torrent C, Vieta E, Viswanath B, Wanchoo MJ, Zetin M, Whybrow PC. Influence of light exposure during early life on the age of onset of bipolar disorder. Journal of Psychiatric Research. 2015; 64:1-8.

58. Bauer M, Glenn T, Alda M, Andreassen OA, Angelopoulos E, Ardau R, Baethge C, Bauer R, Bellivier F, Belmaker RH, Berk M, Bjella TD, Bossini L, Bersudsky Y, Yat Wo Cheung E, Conell J, Del Zompo M, Dodd S, Etain B, Fagiolini A, Frye MA, Fountoulakis KN, Garneau-Fournier J, Gonzalez-Pinto A, Gottlieb JF, Harima H, Hassel S, Henry C, Iacovides A, Isometsä ET, Kapczinski F, Kliwicki S, König B, Krogh R, Kunz M, Lafer B, Larsen ER, Lewitzka U, Lopez-Jaramillo C, MacQueen G, Manchia M, Marsh W, Martinez-Cengotitabengoa M, Melle I, Monteith S, Morken G, Munoz R, Nery FG, O'Donovan C, Osher Y, Pfennig A, Quiroz D, Ramesar R, Rasgon N, Reif A, Ritter P, Rybakowski JK, Sagduyu K, Scippa AM, Severus E, Simhandl C, Stein D, Strejilevich S, Sulaiman AH, Suominen K, Tagata H, Tatebayashi Y, Torrent C, Vieta E, Viswanath B, Wanchoo MJ, Zetin M, Whybrow PC. Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. European Psychiatry 2015 Jan; 30(1):99-105. doi: 10.1016/j.eurpsy.2014.10.005.

59. Rapado-Castro M, Berk M, Venugopal K, Bush AL, Dodd S, Dean OM. Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2015; 57: 69–75.

60. Aggarwal S, Dodd S, Berk M. Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implications. Current Drug Safety. 2015; 10(2): 98-105.

61. Bortolasci CC, Odebrecht Vargas H, Odebrecht Vargas Nunes S, Piccoli de Melo LG, Pizzo de Castro MR, Gastaldello Moreira E, Dodd S, Sabbatini Barbosa D, Berk M, Maes M. Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. Journal of Affective and sertraline exposure compromises Disorders 2015; 179:148-155.

62. Lopatecki A, Dean OM, Davey C, Kerr M, Harrigan S, Chanen A, Dodd S, O’Shea M, Hetrick S, McGorry P, Berk M. Youth Depression Alleviation - Augmentation with an anti-inflammatory agent (YoDA-A): Protocol and rationale for a placebo-controlled randomised trial of rosuvastatin and aspirin. Early Intervention in Psychiatry (In press, accepted September 10 2015).



63. Fraher D, Hodge JM, Collier FM, McMillan JS, Kennedy RL, Ellis M, Nicholson GC,

Walder K, Dodd S, Berk M, Pasco JA, Williams LJ, Gibert Y. Citalopram and sertraline exposure compromises embryonic bone development. Mol Psychiatry 08 Sep 2015.

64. Dodd S, Dean OM, Fernandes BS. Future directions for pharmacotherapies for treatment-resistant bipolar disorder. Current Neuropharmacology. 2015; 13(5): 656-662.

65. Nunes SOV, Piccoli de Melo LG, Pizzo de Castro MG, Barbosa DS, Vargas HO, Berk M, Maes M. Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. Journal of Affective Disorders. 2015;172:55-62.

66. Pizzo de Castro MG, Nunes SOV, Guembarovski RL, Ariza CB, Oda JMM, Vargas HO, Pizzoli de Melo LG, Watanabe MAE, Berk M. Maes M. STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. Journal of Affective Disorders. 2015;172:347-354.

67. Mancuso SG, Morgan VA, Mitchell PB, Berk M, Young A, Castle DJ. A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: results from the Second Australian National Psychosis Survey. Journal of Affective Disorders. 2015;172:30–37.

68. Peters A, Sylvia LG, Da Silva Magalhães PV, Miklowitz DJ, Frank E, Otto MW, Hansen NS, Dougherty DD, Berk M, Nierenberg AA, Deckersbach T. Age at onset, course of illness and response to psychotherapy in bipolar. disorder: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Psychological Medicine 2014;44(16):3455-3467.

69. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of Asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015 Jan 20. [Epub ahead of print].

70. Hosain MK, Kouzani AZ, Tye S, Kaynak A, Berk M. RF rectifiers for EM power harvesting in a Deep Brain Stimulating device. Australas Phys Eng Sci Med. 2015 Jan 20. [Epub ahead of print]

71. Morris G, Berk M, Galecki P, Walder K, Maes M. The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. Mol Neurobiol. 2015 Jan 20. [Epub ahead of print].

72. Amminger GP, Mechelli A, Rice S, Kim SW, Klier CM, McNamara RK, Berk M, McGorry PD, Schäfer MR. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Transl Psychiatry. 2015 Jan 13;5:e495. doi: 10.1038/tp.2014.134.

73. Ghanizadeh A, Berk M. Beta-Lactam Antibiotics as a Possible Novel Therapy for Managing Epilepsy and Autism, A Case Report and Review of Literature. Iran J Child Neurol. 2015 Winter;9(1):99-102.

74. Quirk SE, Williams LJ, Chanen AM, Berk M. Contribution of personality disorder to population mental health and disease burden. The Lancet. Comment. 2015;50(5)807-820.

75. Berk M, Nierenberg AA. Three paths to drug discovery in psychiatry. American Journal Psychiatry. 2015;172(5):412-414.

76. Thomson D, Turner A, Lauder S, Gigler ME, Berk L, Singh AB, Pasco JA, Berk M, Sylvia L. A brief review of exercise, bipolar disorder and mechanistic pathways. Frontiers in Psychology. 2015;6:147.



77. Sarris J, Stough C, Bousman C, Murphy J, Savage K, Smith DJ, Menon R, Chamoli S, Oliver G, Berk M, Byrne GJ, Ng C, Mischoulon D. An adjunctive antidepressant neutraceutical combination in treating major depression: study protocol and clinical considerations. Advances in Integrative Medicine. 2015.

78. Leitan ND, Michalak EE, Berk L, Berk M, Murray G. Optimizing delivery of recovery-oriented online self-management strategies for bipolar disorder: a review. Bipolar Disorders. Review article. 2015 17(2):115-27.

79. Panizzutti B, Gubert C, Schuh AL, Ferrari P, Bristot G, Fries GR, Massuda R, Walz J, Rocha NP, Berk M, Teixeira AL, Gama CS. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker? J Affect Disord. 2015;182:64-69.

80. Dodd S, Schacht A, Kelin K, Duenas H, Reed VA, Williams LJ, Quirk FH, Malhi GS, Berk M. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry 2015;76(6):702-11.

81. Michalak EE, Lane K, Hole R, Barnes SJ, Khatri N, Lapsley S, Maxwell V, Milev R, Parikh SV, Berk L, Berk M, Tse S, Murray G, Perez Algorta G, Lobban F, Jones S, Johnson SL. Towards a better future for Canadians with bipolar disorder: principles and implementation of a community-based participatory research model. Engaged Scholar Journal: Community engaged research, teaching and learning. 2015.

82. Pasco JA, Berk M, Williams LJ, Brennan-Olsen SL, Jacka FN. Milk consumption and the risk for incident major depressive disorder. Psychotherapy and Psychosomatics, 2015, 84(6):384-386.

83. Maes M, Nowak G, Caso JR, Leza JC, Song C, Kubera M, Klein H, Galecki P, Noto C, Glaab E, Balling R, Berk M. Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Mol Neurobiol. 2015; [Epub ahead of print].

84. Berk M. ANZJP This Month. Australian & New Zealand Journal of Psychiatry. 2015;49(5):405-406.

85. Talarowska M, Szemraj J, Berk M, Maes M, Gałecki P. Oxidant/antioxidant imbalance is an inherent feature of depression. BMC Psychiatry. 2015;15:71. doi: 10.1186/s12888-015-0454-5.

86. Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem. 2015;15(5):355-65.

87. Daglas R, Yücel M, Cotton S, Allott K, Hetrick S, Berk M. Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. Int J Bipolar Disord. 2015;3:9.

88. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: a pilot study. Clin Psychopharmacol Neurosci. 2015;13(1):53-61.

89. Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med. 2015 Apr 1;13:68. doi: 10.1186/s12916-015-0310-y.

90. Morris G, Berk M, Walder K, Maes M. Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med. 2015 Feb 6;13:28. doi: 10.1186/s12916-014-0259-2.

91. Ratheesh A, Berk M, Davey CG, McGorry PD, Cotton SM. Instruments that prospectively predict bipolar disorder - A systematic review. J Affect Disord. 2015;179:65-73.



92. Murray G, Leitan ND, Berk M, Thomas N, Michalak E, Berk L, Johnson SL, Jones S, Perich T, Allen NB, Kyrios M. Online mindfulness-based intervention for late-stage bipolar disorder: pilot evidence for feasibility and effectiveness. J Affect Disord. 2015;178:46-51.

93. Kim SW, Jeong BO, Kim JM, Shin IS, Hwang MY, Paul Amminger G, Nelson B, Berk M, McGorry P, Yoon JS. Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. Psychiatry Res. 2015 Mar 30;226(1):368-75.

94. Moylan S, Gustavson K, Øverland S, Karevold EB, Jacka FN, Pasco JA, Berk M. The impact of maternal smoking during pregnancy on depressive and anxiety behaviors in children: the Norwegian Mother and Child Cohort Study. BMC Med. 2015;13:24.

95. Hyde N, Dodd S, Venugopal K, Purdie C, Berk M, O’Neil A. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Current Drug Safety. 2015;10:125-131.

96. Ratheesh A, Cotton SM, Betts JK, Chanen A, Nelson B, Davey CG, McGorry PD, Berk M, Bechdolf A. Prospective progression from high-prevalence disorders to bipolar disorder: Exploring characteristics of pre-illness stages. Journal of Affective Disorders. 2015; 183:45-48.

97. Waterdrinker A, Berk M, Venugopal K, Rapado-Castro M, Turner A, Dean OM. Effects of N-Acetyl Cysteine on suicidal ideation in bipolar depression. Letters to the editor. Journal Clinical Psychiatry. 2015;76(5):665. Epub ahead of print.

98. Galecki P, Talarowska M, Anderson G, Berk M, Maes M. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression. Medical Science Monitor. 2015;21:1535-1547. Review article.

99. Hayley AC, Williams LJ, Venugopal K, Kennedy GA, Berk M, Pasco JA. The relationships between insomnia, sleep apnoea and depression: Findings from the American National Health and Nutrition Examination Survey, 2005-2008. Australian and New Zealand Journal of Psychiatry 2015; 49(2): 156-170. doi: 10.1177/0004867414546700.

100. Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA. Excessive daytime sleepiness and metabolic syndrome: a cross-sectional study. Metabolism. 2015:62(2):244-252.

101. Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M. Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neuroscience and Biobehavioral Reviews. 2015;48:10-21.

102. Carvalho AF, Köhler CA, McIntyre RS, Knöchel C, Brunoni AR, Thase ME, Quevedo J, Fernandes BS, Berk M. Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. Psychoneuroendocrinology. 2015:62:18-26.

103. Aggarwal S, Berk M. Non-suicidal self-injury in Indian adolescents: Nonexistent or unacknowledged? Int J Soc Psychiatry. 2015:61(5):516-7.

104. Kim SW, Dodd S, Berk L, Kulkarni J, de Castella A, Fitzgerald PB, Kim JM, Yoon JS, Berk M. Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder. Psychiatry Investig. 2015:12(3):349-55.

105. Hayley AC, Skogen JC, Sivertsen B, Wold B, Berk M, Pasco JA, Øverland S. Symptoms of depression and difficulty initiating sleep from early adolescence to early adulthood: A longitudinal study. Sleep 2015; 38(1): 1599-1606. doi: 10.5665/sleep.5056.

106. Kale RP, Kouzani AZ, Walder K, Berk M, Tye SJ. Evolution of optogenetic microdevices. Neurophotonics. 2015:2(3):031206.



107. Morris G, Berk M, Walder K, Maes M. The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. Mol Neurobiol. 2015 Jun 17. [Epub ahead of print].

108. Rauma PH, Pasco JA, Berk M, Stuart AL, Koivumaa-Honkanen H, Honkanen RJ, Hodge JM, Williams LJ. The association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in men. J Musculoskelet Neuronal Interact. 2015:15(2):177-85.

109. Yui K, Berk M. Mitochondrial Dysfunction and its relation to translocator protein, oxidative stress, mTOR signaling, and Synaptic Protein. Mini Rev Med Chem. 2015;15(5):353-4. No abstract available.

110. Ghanizadeh A, Singh AB, Berk M, Torabi-Nami M. Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. Expert Opin Ther Targets. 2015:19(7):927-39.

111. Li H, Wang D, Singh LS, Berk M, Tan H, Zhao Z, Steinmetz R, Kirmani K, Wei G, Xu Y. Correction: abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer g protein-coupled receptor 1. PLoS One. 2015:10(4):e0125463.

112. Dean OM, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A, Tangwongchai S, Ng C, Dowling N, Malhi GS, Berk M. Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial. Clin Psychopharmacol Neurosci. 2014 Dec;12(3):180-188. Epub 2014 Dec 26

113. Rauma PH, Pasco JA, Berk M, Stuart AL, Koivumaa-Honkanen H, Honkanen RJ, Hodge JM, Williams LJ. The association between use of antidepressants and bone quality using quantitative heel ultrasound. Australian and New Zealand Journal of Psychiatry 2015; 49(5): 437-443. doi: 10.1177/0004867414565475

114. Sarris J, Stough C, Bousman C, Murphy J, Savage K, Smith DJ, Menon R, Chamoli S, Oliver G, Berk M, Bryne GJ, Ng C, Mischoulon D. An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Advance in Integrative Medicine 2 (2015) 49-55.

115. de Souza Gomes JA, de Souza GC, Berk M, Cavalcante LM, de Sousa FC, Budni J, de Lucena DF, Quevedo J, Carvalho AF, Macêdo D Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. Eur Neuropsychopharmacol. 2015 Aug 17. pii: S0924-977X(15)00258-8.

116. Hosain MK, Kouzani AZ, Tye SJ, Samad MF, Kale RP, Bennet KE, Manciu FS, Berk M. Radio frequency energy harvesting from a feeding source in a passive deep brain stimulation device for murine preclinical research. Med Eng Phys. 2015 Aug 26. pii: S1350-4533(15)00175-7.

117. Morris G, Walder K, Puri BK, Berk M, Maes M. The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders. Mol Neurobiol. 2015 Aug 27. [Epub ahead of print].

118. Malhi GS, Berk M. Depolarising bipolarity: Clinical considerations. Aust N Z J Psychiatry. 2015 Sep;49(9):767-9.

119. Martin-Subero M, Anderson G, Kanchanatawan B, Berk M, Maes M. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut-brain pathways. CNS Spectr. 2015 Aug 26:1-15. [Epub ahead of print].



120. Kim SW, Bae KY, Kim JM, Shin IS, Hong YJ, Ahn Y, Jeong MH, Berk M, Yoon JS. The use

of statins for the treatment of depression in patients with acute coronary syndrome. Transl Psychiatry. 2015 Aug 18;5:e620.

121. Smesny S, Milleit B, Schaefer MR, Hipler UC, Milleit C, Wiegand C, Hesse J, Klier CM, Holub M, Holzer I, Berk M, McGorry PD, Sauer H, Paul Amminger G. Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. Prostaglandins Leukot Essent Fatty Acids. 2015 Jul 21. pii: S0952-3278(15)00135-0.

122. Moylan S, Eyre HA, Berk M. Chronic fatigue syndrome: what is it and how to treat? The Lancet, Epub ahead of print.

123. Jacka FN, Berk M. Gut dysbiosis in mania: a viable therapeutic target. ANZJP. Epub ahead of print.

124. Berk M. The classification of biomarkers. JAMA Psychiatry. Epub ahead of print. 125. Berk M. From risk to remediation. Australian New Zealand Journal Psychiatry.

2015;49(10):857-858. 126. Berk M. N-Acetylcysteine for Huntington’s. Australian New Zealand Journal Psychiatry.

2015; Epub ahead of print. 127. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. The Lancet. 2015; Epub

ahead of print. 128. Kale RP, Kouzani AZ, Berk M, Walder K. Berk J, Tye SJ. Wireless optogenetics: an

exploration of portable microdevices for small animal photostimulation. Science Direct. 2015:225-230.

129. Brennan SL, Holloway KL, Williams LJ, Kotowicz MA, Bucki-Smith G, Moloney DJ, Dobbins AG, Timney EN, Pasco JA. The social gradient of fractures at any skeletal site in men and women: data from the Geelong Osteoporosis Study Fracture Grid. Osteoporosis International 2015; 26(4): 1351-1359. doi: 10.1007/s00198-014-3004-y.

130. Quirk SE, Williams LJ, Chanen AM, Berk M. Personality disorder and population mental health. Lancet Psychiatry 2015 2: 201-202.

131. Brennan-Olsen SL, Williams LJ, Dobbins AG, Holloway KL, Hosking SM, Stuart AL, Pasco JA. Socioeconomic status and all-cause mortality: Data from the Geelong Osteoporosis Study female cohort (accepted Preventative Medicine 16/5/14).

132. Hayley AC, Skogen JC, Øverland S, Wold B, Kennedy GA, Williams LJ, Sivertsen B. Trajectories and stability of self-reported short sleep duration from adolescence to adulthood. Journal of Sleep Research 2015 Jul 14. doi: 10.1111/jsr.12316. [Epub ahead of print].

133. Stuart AL, Pasco JA, Jacka FN, Berk M, Williams LJ: Falls and depression in men - A population-based study. (accepted to Journal of Mens Health 09/09/15).

134. Williams LJ, Jacka FN, Pasco JA, Coulson C, Quirk SE, Stuart AL, Berk M. The prevalence and age of onset of psychiatric disorders in Australian men (accepted ANZJP 1/10/15).

135. de Abreu LLF, Holloway KL, Kotowicz MA, Pasco JA. Dysglycaemia and other predictors for progression or regression from impaired fasting glucose to diabetes or normoglycaemia. Journal of Diabetes Research 2015;2015:373762. doi:10.1155/2015/373762.

136. Barker AL, McNeil JJ, Ward SA, Sanders KM, Khosla S, Cumming RG, Seeman E, Pasco JA, Bohensky MA, Ebeling PR, Woods RL, Lockery JE, Wolfe R, Talevski J and the ASPREE Investigator Group. A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: Protocol for the ASPREE-Fracture sub-study. Injury Prevention 2015 May 21 [Epub ahead of print]. doi: 10.1136/injuryprev-2015-041655.

137. Fernandes BS, Berk M, Pasco JA, Hodge JM, Lana Williams LJ. Effects of depression and serotonergic antidepressants on bone: Mechanisms and implications for the treatment of depression. Drugs & Aging 2015 IN PRESS (accepted 19/10/2015).



138. Harding J, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Briffa T, Davis TM, Davis

WA, Dobson A, Giles GG, Grant J, Knuiman M, Luszcz M, Mitchell P, Pasco JA, Reid C, Simmons D, Simons L, Tonkin A, Woodward M, Shaw JE, Magliano DJ. The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components? Diabetes Metabolism 2015 May 30. doi: 10.1016/j.diabet.2015.04.006. [Epub ahead of print]

139. Leslie WD, Brennan SL, Morin SN, Lix LM. Fracture prediction from repeat BMD measurements in clinical practice. Osteoporosis International IN PRESS (accepted 10/07/2015).

140. O’Neil A, Shivappa N, Jacka FN, Kotowicz MA, Kibbey K, Hebert JR, Pasco JA. Pro-inflammatory dietary intake as a risk factor for cardiovascular disease in men: a 5-year longitudinal study. British Journal of Nutrition 2015 Oct 9: 1-9 [Epub ahead of print].

141. Scott D, McLaughlin P, Nicholson GC, Ebeling PR, Stuart AL, Kay D, Sanders KM. Changes in gait performance over several years are associated with recurrent falls status in community-dwelling older women at high risk of fracture. Age and Aging 2015; 44(2): 287-293. doi: 10.1093/ageing/afu169

142. Dean OM, Mancuso SG, Bush AI, Copolov D, Cuenod M, Conus P, Rossell SL, Castle DJ, Berk M. Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Letter to the Editor. Psychiatry Research. 2015;230(3):982-983.

143. Williams LJ, Pasco JA, Jackson H, Kiropoulos L, Stuart AL, Jacka FN, Berk M. Depression as a risk factor for fracture in women: a 10 year longitudinal study. Journal of Affective Disorders. 2015.

144. Peters AT, Shesler LW, Sylvia L, Magalhães PVS, Miklowitz DJ, Otto MW, Frank E, Berk M, Dougherty DD, Nierenberg AA, Deckersbach T. Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. ANZJP. 2015.

145. Fernandes BS, Molendijk ML, Kohler CA, Soares JC, Leite CMGS, Machado-Vieira R, Ribeiro TL, Silva JC, Sales PMG, Quevedo J, Oertel-Knochel V, Vieta E, Gonzalez-Pinto A, Berk M, Carvalho AF. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Medicine, 2015;13:289.

146. Quirk SE, Berk M, Chanen AM, Koivumaa-Honkanen H, Brennan-Olsen SL, Pasco JA, Williams LJ. Personality disorders: theory, research and treatment. Online First Publication. 2015.

147. Aggarwal S, Berk M, Taljard L, Wilson Z. South African adolescents’ beliefs about depression. International Journal of Social Psychiatry. 2015; Letter to the Editor

148. Berk L, Berk M. Who cares about carers? ANZJP. 2015. 149. Pasco JA, Foulkes C, Doolan B, Brown K, Holloway KL, Brennan-Olsen SL. A conduit

between epidemiological research and regional health policy. Australian and New Zealand Journal of Public Health IN PRESS (accepted 10/12/2015).

150. Orford NR, Lane SE, Bailey M, Pasco JA, Cattigan C, Elderkin T, Brennan-Olsen SL, Bellomo R, Cooper DJ, Kotowicz MA. Changes in bone mineral density in the year after critical illness. American Journal of Respiratory and Critical Care Medicine. Accepted November 2015.

151. Jacka FN. No association of dietary patterns with cancer or cardiovascular disease in older adults Clinical Nutrition 2015 (letter, published online Dec).

152. Jacka FN. Lifestyle factors in preventing mental health disorders: an interview with Felice Jacka BMC Medicine 2015; 13:264.

153. Logan A, Jacka F, Craig J, Prescott S. The Microbiome and Mental Health: Looking Back, Moving Forward with Lessons from Allergic Diseases. Clinical Psychopharmacology and Neuroscience published online November 2015.



154. Jacka FN & Berk M. Gut dysbiosis in mania – a viable therapeutic target? (letter to the editor) ANZJP 2015.

155. Brennan-Olsen SL, Page RS, Berk M, Riancho JA, Leslie WD, Wilson SG, Saban KL, Janusek L, Pasco JA, Hodge JM, Quirk SE, Hyde NK, Hosking SM, Williams LJ. DNA methylation and the social gradient of osteoporotic fracture: A conceptual model. Bone IN PRESS (accepted 22/12/2015).

156. Quirk SE, Stuart AL, Brennan-Olsen SL, Pasco JA, Berk M, Chanen AM, Koivumaa-Honkanen H, Kotowicz MA, Lukkala PS, Williams LJ. Physical health comorbidities in women with personality disorder: data from the Geelong Osteoporosis Study. European Psychiatry. Accepted 24/12/2015

Books and chapters 2015

1. Berk M, Otmar R, Dean O, Berk L, Michalak E. Chapter Six: The Use of Mixed Methods in Drug Discovery: Integrating Qualitative Methods into Clinical Trials. Clinical Trial Design Challenges in Mood Disorders. 2015.

2. Kapczinski F, Vieta E, Magalhães PVS, Berk M. Neuroprogression and staging in bipolar disorder. Edit. Wisepress.com 2015.


Conference presentations 2015

2nd APS College of Counselling Psychologists’ Conference. Melbourne, Australia. 26 February – 01 March 2015.

• Burke LM, Quirk SE, Williams LJ, Berk M, Pasco J. (2015). Supporting clients with the grief of mental illness. (Oral)

23rd European Congress of Psychiatry. Vienna, Austria. 28-31 March 2015.

• Berk M. Neuroprotection in the aftermath of a first episode of mania.

• Dodd S. Re-conceptualising major psychosis and mood disorders as staged illnesses: towards change in clinical services and treatment.

Dutch Association of Psychiatry conference. Amsterdam, The Netherlands 31 March – 02 April 2015.

• Berk M. The staging and treatment of bipolar disorder.

• Berk M. Pharmacotherapy of bipolar disorders beyond guidelines.

37th Annual Conference of the Association for Death Education and Counseling. San Antonio, Texas. 08 -11 April 2015.

• Burke LM, Quirk SE, Williams LJ, Berk M, Pasco, J. (2015). “The culture of crazy”: Reflections on loss and grief in mental illness. (Oral)

DOHaD Society Melbourne. Melbourne, Australia. 17-19 April 2015.

• Jacka FN. Predictors of child and adolescent mental health - can we make a difference? How, what and when?

ACNEM Nutrition in Medicine conference. Melbourne, Australia. 02-03 May 2015.

• Berk M. Depression is an inflammatory disease but where does the inflammation come from, and how can we change this? (Plenary)

• Jacka FN. Developmental Origins of Mental Health and Brain Function: focus on diet in the preconception and antenatal periods. (Plenary)

Australasian Podiatry Conference. Gold Coast, Australia. 06-08 May 2015.

• Butterworth PA, Menz HB, Urquhart DM, Cicuttini FM, Pasco JA, Brennan SL, Wluka AE, Strauss BJ, Proietto J, Dixon JB, Jones G, Landorf KB. The association between obesity and foot pain: metabolic, biomechanical or both? (Oral)

In-FLAME. Marburg, Germany. 02-04 June 2015.

• Jacka FN. Inflammation, the microbiome and the brain: Diet as anti-aging strategies in early life. (Keynote, invited meeting).


Conference presentations continued…

International Society for Bipolar Disorders Conference. Toronto, Canada. 03-06 June 2015.

• Gliddon E, Lauder S, Berk L, Cosgrove V, Grimm D, Dodd S, Suppes T, Berk, M. Discussion board engagement in the MoodSwings 2.0 online self-help program for bipolar disorder.

• Gliddon E, Lauder S, Cosgrove V, Grimm D, Dodd S, Suppes T, Berk M. The pros and cons of online recruitment.

• Lauder S, Cosgrove V, Gliddon E, Grimm D, Dodd S, Suppes T, Berk, M. MoodSwings 2.0: An online intervention for bipolar disorder.

• Cosgrove V, Grimm D, Gliddon E, Lauder S, Dodd S, Berk M, Suppes T. Ethical dilemmas of participant safety monitoring in online clinical research.

• Berk L, Gliddon E, Suppes T, Cosgrove V, Deckersbach T, Austin D, Lewis A, Lauder S, Grimm D, & Berk M. Development of an online interactive self-help programs for significant others: www.iCARE4bipolar.com.

2015 Mental Health in Schools Conference. Sydney, Australia. 11-12 June 2015.

• Jacka FN. Diet Quality and Mental Health in Children and adolescents: Updates and New Directions. (Keynote)

12th World Congress of Biological Psychiatry (WFSBP). Athens, Greece. 14-18 June 2015.

• Berk M. Neurocognitive and functional impairment in mood disorders.

• Berk M. Cognitive neuroscience. 002 Clinical Assessment of Neurocognition - the basis for improved clinical outcomes.

• Berk M. The comorbidity of mental & bone health a fracture line ready to break.

• Berk M. Depression: basic/clinical. 004 Treating bipolar disorder in the real world integrating comorbidity into treatment decisions.

I Jornada Internacional de Psicogeriatría, Medicina Psicosomática y Psiquiatría de Enlace. Pontificia Universidad Javeriana. Bogota, Colombia. 21 June 2015.

• Dodd S. Reconceptualización de psicosis y trastornos de ánimo con estadiaje.



Royal Australia and New Zealand College of Psychiatrists (RANZCP). Tasmania, Australia. 06 July 2015.

• Berk M. From neuroprogression to Neuroprotection: new treatments for mood disorders.

2015 Association for the Scientific Study of Consciousness Annual Conference. Paris, France. 07-10 July 2015.

• Giorlando F, Markanday S, Dahler J, Anderson AJ, Fletcher P, Berk M . Inverted Time perception: understandings from MRI and EEG.

Western Alliance Symposium. Ballarat, Australia. 21 August 2015.

• Brennan-Olsen SL, Williams LJ, Pasco JA. The social gradient of osteoporosis and osteoarthritis: Effective conduits to elucidate social-structural factors associated with disease and health service utilisation. (Oral)

• Holloway KL, Sajjad MA, Brennan-Olsen SL, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning T, Brumby S, Page R, Pedler D, Sutherland A, Venkatesh S, Pasco JA. The epidemiology of joint replacements in Western Victoria. (Poster and panel)

• Pasco JA, Brennan-Olsen SL, Holloway KL, Bucki-Smith G, Williams LJ, Morse AG, Stuart AL, Hyde NK, Hosking SM, Quirk SE, Dipnall JF, Sajjad MA, De Abreu L, Doolan BJ, Bennett K, Kotowicz MA. Multifaceted applications of big databases for population-based research: achieving better health for our region. (Oral)

• Pasco JA, Foulkes C, Brown K, Doolan BJ, Brennan SL. A conduit between epidemiological research and regional health policy. (Poster and panel)

• Sajjad MA, Holloway KL, Brennan-Olsen SL, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning T, Brumby S, Page R, Pedler D, Sutherland A, Venkatesh S, Pasco JA. Ageing, Chronic Disease and Injury (ACDI) study: Cancer incidence in Western Victoria. (Oral)

European College of Neuropsychopharmacology (ECNP). Amsterdam, The Netherlands. 29 August – 01 September 2015.

• Berk M. Epidemiology of suicide in bipolar disorder (Sycrest symposium).

Global Prevention Consortium. (Invited meeting). Bergen, Norway. 17-18 September 2015.

• Jacka FN. Addressing maternal nutrition and gut health in the preconception and antenatal period to improve outcomes for children. (Keynote)



STATA conference. Canberra, Australia. 24-25 September 2015.

• Dipnall J, Pasco JA, Berk M, Williams LJ, Dodd S, Jacka FN, Meyer D. Identifying biomarkers in epidemiological studies using a fusion of data mining and traditional statistical techniques in Stata. (Oral)

XVIII National Congress of Psychiatry – Spain. 24-26 September 2015.

• Jacka FN. Inflammation, microbiota and brain: the diet as a prevention strategy at the beginning of life. (Invited oral)

15th International Federation for Psychiatric Epidemiology (IFPE). Bergen, Norway. 07-10 October 2015.

• Jacka FN. The epidemiology of nutrition and mental health and the potential for prevention. (Opening plenary)

• Dash S, Shivappa N, Herbert J, O’Neil A, Stuart A, Williams LJ, Pasco JA, Jacka FN. An inflammatory dietary pattern is associated with increased psychological symptoms in Australian women. (Poster)

• Pasco JA, Williams LJ, Brennan-Olsen SL, Berk M, Jacka FN. Milk consumption and the risk for incident MDD. (Oral)

• Quirk SE, Stuart AL, Brennan-Olsen SL, Pasco JA, Berk M, Chanen AM, Koivumaa-Honkanen H, Lane S, Moran P, Borchmann R, Bolton J, Sareen J, Williams LJ. Associations between personality disorders and utilization of medical and mental health care services in a population-based sample. (Oral)

• Williams LJ, Pasco JA, Jackson H, Kiropoulo L, Stuart AL, Jacka FN, Berk M. Depression as a risk factor for fracture in women: cross sectional and longitudinal evidence. (Oral)

• Jacka FN, Cherbouin N, Sachdev P, Anstey K, Butterworth P. Dietary patterns and hippocampal volume in humans: the PATH through life study. (Plenary)

American Society for Bone and Mineral Research (ASBMR). Seattle, Washington, USA. 9-12 October 2015.

• Brennan-Olsen SL, Page RS, Saban KL, Berk M, Wilson SG, Richards B, Riancho JA, Leslie WD, Pasco JA, Hyde NK, Hosking SM, Williams LJ. Does DNA Methylation Underpin the Social Gradient of Osteoporotic Fracture? A Conceptual Model. (Sponsored by Sharon Brennan-Olsen). (Poster)

• Holloway KL, Bucki-Smith G, Morse AG, Brennan-Olsen SL, Kotowicz MA, Moloney DJ, Timney EN, Dobbins AG, Pasco JA. Humeral fractures in south-eastern Australia: epidemiology and risk factors. (Sponsored by Mark Kotowicz). (Poster)

• Pasco JA, Kotowicz MA, Brennan-Olsen SL, Holloway KL, Jacka FN, Berk M, Quirk SE, Stuart AL, Williams LJ. Appendicular lean mass and de novo anxiety: A potential regulatory role for skeletal muscle on brain function. (Sponsored by Julie Pasco). (Poster)



Australian & New Zealand Obesity Society (ANZOS). Melbourne, Australia. 15-17 October 2015.

• Chou L, Brady SRE, Urquhart DM, Teichtahl AJ, Cicuttini FM, Pasco JA, Brennan-Olsen SL, Wluka AE. The relationship between obesity and low back pain and disability is affected by mood disorders – A population-based, cross-sectional study of men. (Oral)

• Jacka FN. Developmental origins of obesity workshop. Panellist on “cohorts, trials and future directions”.

The Australasian Marcé Society 2015 Conference. Adelaide, Australia. 22-24 October 2015.

• Jacka FN. Developmental Origins of Mental Health and Brain Function: focus on diet in the preconception and antenatal periods. (Keynote)

The Ancestral Health Society of New Zealand (AHSNZ). Queenstown, New Zealand. 23-25 October 2015.

• Jacka FN. The critical importance of diet to mental health across the lifespan. (Closing keynote)

Royal Australian and New Zealand College of Psychiatry – Victorian Branch Conference. Melbourne, Australia. 25 October 2015.

• Dean OM. Square pegs for round holes? Repurposing medical treatments for psychiatry. (Invited speaker)

Australian and New Zealand Bone and Mineral Society (ANZBMS). Hobart, Tasmania, Australia. 01-04 November 2015.

• Yousif D, Bucki-Smith G, Morse A, Kotowicz M, Pasco J, Holloway K. Lower limb fractures at a regional university hospital. (Poster)

• Holloway KL, Sajjad MA, Brennan-Olsen SL, Kotowicz MA, Graves S, Kelly L, Livingston PM, Khasraw M, Hakkennes S, Dunning T, Brumby S, Page R, Pedler D, Sutherland A, Venkatesh S, Pasco JA. The epidemiology of joint replacements in Western Victoria: the Ageing, Chronic Disease and Injury (ACDI) study. (Poster)

• Hosking S, Buchbinder R, Brennan-Olsen S, Hyde N, Williams L, Pasco J. Maternal health literacy and child bone mineral density. (Poster)

• Hyde NK, Hosking SM, Brennan-Olsen SL, Wark JD, Bennett K, Morse AG, Pasco JA. Gestational vitamin D status and offspring bone mass at age 10-12 years. (Poster)

• Pasco JA, Mohebbi M, Holloway KL, Brennan-Olsen SL, Kotowicz MA. Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study. (Poster)

• Stuart AL, Quirk SE, Pasco JA, Berk M, Brennan-Olsen SL, Williams LJ. Quantitative heel ultrasound in bipolar disorder: A case control study. (Poster)



Australian Association of Gerontology. Alice Springs, Australia. 04-06 November 2015.

• Brennan-Olsen SL, Page RS, Lane SE, Lorimar M, Buchbinder R, Osborne RH, Pasco JA, Wluka AE, Sanders KM, Ebeling PE, Graves SE. Do geographic and socioeconomic variations exist in shoulder joint replacements? (Oral)

• Holloway KL, Henry MJ, Brennan-Olsen SL, Bucki-Smith G, Nicholson GC, Koran S, Pasco JA, Kotowicz MA. Non-hip and non-vertebral fractures in older adults: the neglected fracture sites. (Oral)

33rd Brazilian Congress of Psychiatry. Florianopolis, Brazil. 04-07 November 2015.

• Jacka FN. Diet as a modifiable risk factor and treatment option for depressive illness. (Plenary)

American College of Rheumatology (ACR). San Francisco, USA. 06-11 November 2015.

• Chou L, Brady SRE, Urquhart DM, Teichtahl AJ, Cicuttini FM, Pasco JA, Brennan-Olsen SL, Wluka AE. The relationship between obesity and low back pain and disability is affected by mood disorders – A population-based, cross-sectional study of men. (Poster)

Australian Society for Bipolar & Depressive Disorders (ASBDD). Sydney, Australia. 6-8 November 2015.

• Williams LJ, Pasco JA, Hodge JM, Berk M. Mood disorders, psychotropic use and bone health. (Oral)

• Dodd S. Can we identify which patients are most likely to have a nocebo response? Results from meta-analyses of the placebo arms of clinical trials.

• Gliddon E, Lauder S, Berk L, Berk M. Discussion Board Engagement in the MoodSwings 2.0 Online Intervention for Bipolar Disorder. (Oral)

• Fernandes B. C-Reactive Protein as a Biomarker in Bipolar Disorder: a Systematic Review and Meta-analysis. (Oral)

• Fernandes BS, Berk M. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. (Poster)

• Fernandes BS, Dodd S, Dean O, Berk M. N-acetyl cysteine decreases depressive symptoms and improves functionality: a systematic review and meta-analysis. (Poster)

• Berk M. Novel therapies for psychiatric disorders: from translation to implementation. (Opening address)

• Dean O. Minocycline: antibiotic to antidepressant. (Invited Speaker) Chair – ECR open communication session

• Lauder S. Hot and manic, cold and depressed: Associations between meteorological changes and mood transitions in bipolar 1 disorder. (Oral)

Continued…



Australian Society for Bipolar & Depressive Disorders (ASBDD). Sydney, Australia. 6-8 November 2015. Continued…

• Williams LJ, Pasco JA, Hodge JM, Berk M. Mood disorders, psychotropic use and bone health. (Oral)


• Gliddon E, Lauder S, Berk L, Berk M. Discussion Board Engagement in the MoodSwings 2.0 Online Intervention for Bipolar Disorder. (Oral)

• Fernandes B. C-Reactive Protein as a Biomarker in Bipolar Disorder: a Systematic Review and Meta-analysis. (Oral)

• Fernandes BS, Berk M. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. (Poster)

• Fernandes BS, Dodd S, Dean O, Berk M. N-acetyl cysteine decreases depressive symptoms and improves functionality: a systematic review and meta-analysis. (Poster)

• Berk M. Novel therapies for psychiatric disorders: from translation to implementation. (Opening address)

• Dean O. Minocycline: antibiotic to antidepressant. (Invited Speaker) Chair – ECR open communication session

• Lauder S. Hot and manic, cold and depressed: Associations between meteorological changes and mood transitions in bipolar 1 disorder. (Oral)

World Congress on Developmental Origins of Health and Disease (Doha). Cape Town, South Africa. 08-11 November 2015.

• Hyde NK, Brennan-Olsen SL, Wark JD, Moloney DJ, Bennett K, Pasco JA. Is smoking during pregnancy adversely affecting offspring bone development? (Mini poster/oral)

• Hyde NK, Brennan-Olsen SL, Pasco JA. Maternal dietary mineral intake during gestation and the association with infant crown-heel length. (Mini oral/poster)



Barwon Health Research Week. Geelong, Australia. 09-11 November 2015.

• Brennan-Olsen SL, Hosking SM, Doolan BJ, Williams LJ, Pasco JA. The Fracture Stack: Visualising the population-wide impact of broken bones. (Poster)

• Yousif D, Bucki-Smith G, Morse A, Kotowicz M, Pasco J, Holloway K. Lower limb fractures at a regional university hospital. (Poster)

• Gliddon E, Lauder S, Berk L, Berk M. Discussion board engagement in the MoodSwings 2.0 online intervention for bipolar disorder.

• Gliddon E, Martini T, Lauder S, Berk L, Dodd S, Berk M. The online audience: User characteristics from the MoodSwings online self-help program for bipolar disorder.

• Stuart AL, Quirk SE, Pasco JA, Berk M, Brennan-Olsen SL, Williams LJ. Quantitative heel ultrasound in bipolar disorder: A case control study. (Poster)

• Quirk SE, Stuart AL, Berk M, Brennan-Olsen SL, Pasco JA, Chanen AM, Koivumaa-Honkanen H, Lane SE, Moran P, Borsch Mann R, Bolton JM, Sareen J, Williams LJ. Utilisation of health services by women with personality disorder: a population-based study.

• Burke LM, Berk M, Pasco JA, Williams LJ. The Keebler-Ross legacy: Progressing the field of death, dying, grief, and loss.

National Institute of Integrative Medicine (NIIM). 2nd Annual NIIM Symposium. Advances in Integrated Medicine. Melbourne, Australia. 28 November 2015.

• Jacka FN. Inflammation, the microbiome and brain: diet as a prevention strategy in early life. (Keynote)

Society for Mental Health Research (SMHR). Brisbane, Australia. 02-04 December 2015.


• Stuart AL, Quirk SE, Brennan-Olsen SL, Pasco JA, Lane SE, Berk M, Williams LJ. Utilisation of mental health-related services in females with mood and anxiety disorders: Data from a population-based study.

• Jacka FN, O’Neil A, Itsiopoulos C, Castles D, Opie R, Dash S, Cotton S, Mihalopoulos C, Brazionis L, Hodge A, Berk M. A randomised, controlled trial of a dietary intervention for adults with major depression (the “SMILES” trial).

• Burke LM, Berk M, Pasco JA, Williams LJ. The Kubler-Ross legacy: Progressing the field of death, dying, grief, and loss.

Continued…



Society for Mental Health Research (SMHR). Brisbane, Australia. 02-04 December 2015. Continued…

• Dipnall JF, Pasco JA, Berk M, Williams LJ, Dodd S, Jacka FN, Meyer D. Can data mining and machine learning help us find biomarkers associated with depression in epidemiological studies?

• O’Neil A, Fisher AJ, Kibbey K, Jacka FN, Kotowicz MA, Williams LJ, Stuart AL, Berk M, Lewandowski PA, Atherton JJ, Taylor CB, Pasco JA. Depression is a risk factor for incident coronary heart disease in women: an 18-year longitudinal study. (Oral)

• O’Neil A, Fisher AJ, Kibbey K, Jacka FN, Kotowicz MA, Williams LJ, Stuart AL, Berk M, Lewandowski PA, Atherton JJ, Taylor CB, Pasco JA. The addition of depression to the Framingham Risk Equation model improves risk prediction for coronary heart disease in women.

• Quirk SE, Stuart AL, Berk M, Brennan-Olsen SL, Pasco JA, Chanen AM, Koivumaa-Honkanen H, Lane SE, Moran P, Borschmann R, Bolton JM, Sareen J, Williams LJ. Utilisation of health services by women with personality disorder: a population-based study.

• Williams LJ, Pasco JA, Jackson H, Kiropoulos L, Stuart AL, Jacka FN, Berk M. Depression as a risk factor for fracture: cross-sectional and longitudinal evidence.

• Gliddon E, Lauder S, Berk L, Berk M. Discussion board engagement in the MoodSwings 2.0 online intervention for bipolar disorder.

• Williams LJ. Depression as a risk factor for fracture: cross sectional and longitudinal evidence.

• Dean OM. Antibiotics in Psychiatry. • Berk M. Something old, something new,

something borrowed: Not so blue? • Dash S, Shivappa N, Herbert J, O’Neil A, Stuart A,

Williams LJ, Pasco JA, Jacka FN. An inflammatory dietary pattern is associated with increased psychological symptoms in Australian women.

International Diabetes Epidemiology Group (IDEG). Vancouver, Canada. 05-06 December 2015.

• Harding JL, Nedkoff L, Shaw JE, Magliano DJ, on behalf of the ANZDCC group. Differences in absolute and relative risks for CVD mortality among various low and high risk groups: exploring the phenomenon.

Genetics Symposium. Herzenberg Nexus. Stanford University. Palo Alto, California, USA. 16-18 December 2015.

• Berk M. Biomarkers as targets for novel therapies for neuropsychiatric disorders


IMPACT SRC Contacts

Professor Michael Berk, Health Education Research Building (HERB) Level 3, rear of

Kitchener House, 285 Ryrie Street, PO Box 281

Geelong Victoria 3220 Australia

Phone: +61 3 4215-3330, Fax: +61 3 4215-3491

email: [email protected]

Professor Julie Pasco, Health Education Research Building (HERB) Level 3, rear of

Kitchener House, 285 Ryrie Street, PO Box 281

Geelong Victoria 3220 Australia

Phone: +61 3 4215-3331, Fax: +61 3 4215-3491

email: [email protected]

Brianna Doolan, Communications Officer and Research Assistant

Email: [email protected]

Website: https://www.deakin.edu.au/research/impact

Follow us on Twitter: @IMPACTSRC

Original photographs by G Berk

Documents

Annual Report 2015 draft as at 23 12 15 (Autosaved)...antidepressant effects. We are completing the first study of minocycline, an antibiotic with anti-inflammatory properties in depression